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4 Abstract 
ABSTRACT
Keratins (K) are cytoskeletal proteins mainly expressed in the epithelium and constitute 
the largest subgroup of intermediate filaments (IFs). Simple epithelial keratins (SEKs) 
K7-K8 and K18-K20 are the major IF elements in the colon. SEK mutations are known 
to cause around 30 human diseases, mainly affecting liver and skin. However, so far no 
strong associations between K8 mutations and the development of human colitis have 
been found. The keratin contribution to colonic health comes from the K8 knock-out 
(K8-/-) mouse model, which develops an early chronic inflammation and hyperproliferation 
in the colon. The aim of this thesis was to investigate how keratins contribute to 
intestinal health and disease mainly by the experimental analysis using the K8-/- mouse 
colon and cell culture models. The work described here is divided into three studies. 
The first study revealed involvement of keratins in Notch1 signaling, which is the master 
regulator of cell fate in the colon. Immunoprecipitation and immunostaining, both 
in vitro and in vivo showed that K8 binds and co-localizes with Notch1. Interestingly, 
overexpression of keratins enhanced Notch1 levels and stabilized Notch intracellular 
domain (NICD), leading to higher activity of Notch signaling. The dramatic decrease 
in Notch activity in the K8-/- colon resulted in a differentiation shift towards goblet 
and enteroendocrine cells. The second study focused on the involvement of keratins 
in colitis-associated cancer (CAC). Although, the K8-/- inflamed colon did not 
develop colorectal cancer (CRC) spontaneously, it was dramatically more susceptible 
to induced CRC in two CRC models: azoxymethane (AOM) and multiple intestinal 
neoplasia (ApcMin/+). To understand how the loss of K8 contributes to CAC, the 
epithelial inflammasome signaling pathway was analyzed. The released component 
of active inflammasome, cleaved caspase-1 and its downstream protein, interleukin 
(IL)-18, were significantly increased in K8-/- and K8-/-ApcMin/+ colons. The inflammasome 
pathway has recently been suggested to control the levels of IL-22 binding protein 
(IL-22BP), which is a negative regulator of IL-22 activity. Interestingly, the activated 
inflammasome correlated with an upregulation of IL-22 and a complete loss of 
IL-22BP in the K8-null colons. The activation of IL-22 was confirmed by increased levels 
of downstream signaling, which is phosphorylated signal transducer and activator of 
transcription 3 (P-STAT3), a transcription factor promoting proliferation and tissue 
regeneration in the colon. The objective of the third study, was to examine the role of 
keratins in colon energy metabolism. A proteomic analysis identified mitochondrial 
3-hydroxy-3-methylglutaryl-CoA synthase 2 (HMGCS2) as the major downregulated 
protein in the K8-/- colonocytes. HMGCS2 is the rate-limiting enzyme in ketogenesis, 
where energy from bacterially produced short chain fatty acids (SCFAs), mainly 
butyrate, is converted into ketone bodies in colonic epithelium. Lower levels and activity 
of HMGCS2 in the K8-/- colon resulted in a blunted ketogenesis. The studies upstream 
from HMGCS2, identified decreased levels of the SCFA-transporter monocarboxylate 
transporter 1 (MCT1), which led to increased SCFA content in the stool suggesting 
impaired butyrate transport through the colonic epithelium. Taken together, the results 
of the herein thesis indicate that keratins are essential regulators of colon homeostasis, in 
particular epithelial differentiation, tumorigenesis and energy metabolism. 
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SAMMANFATTNING
Keratiner (K) är den största gruppen av intermediärfilament (eng. intermediate filaments, 
IFs) och de uttrycks i alla kroppens epitel liksom även i tarmen. I tjocktarmens epitellager 
är de enkla epitelets keratiner (eng. simple epithelial keratins, SEKs) K7-K8 och K18-K20, 
de vanligaste keratinerna. Mutationer i SEKs förorsakar eller bidrar till ca 30 sjukdomar hos 
människan, främst i lever och hud. Det är dock ännu oklart ifall keratinerna har en skyddande 
roll mot tarmsjukdomar, vilket inte är osannolikt efterom K8-knock-out mus-modellen 
(K8-/-) utvecklar en tidig kronisk inflammation i tjocktarmen samt en hyperproliferering 
av tjocktarmsepitelet. Målsättningen med denna avhandling var att undersöka hur 
keratinerna bidrar till upprätthållningen av tarmhälsan, vilket i huvudsak gjordes genom 
att undersöka tarmepitelet hos K8-/- musen och med hjälp av cellkulturmodeller. Detta 
arbete är uppdelat i tre delarbeten. Det första delarbetet visade att keratinerna samverkar 
med Notch1-signalleringen, vilken är den väsentligaste regleringsräckan som styr cellernas 
differentiering och öde. En dramatisk nedreglering av Notch1 observerades i K8-/- musens 
tjocktarmsepitel, där följdaktligen celldifferentieringen påverkades. Både in vivo och in vitro 
immunoprecipitering och immunofärgning påvisade att K8/K18 binder och kolokaliserar 
med Notch1. Dessutom påvisades att en överexpression av keratiner ökade nivåerna av 
Notch1 och stabiliserade den intracellulära delen av Notch (eng. Notch intracellular 
domain, NICD), vilket vidare leder till ökad Notch signalering. Nästa delarbete fokuserade 
på keratinernas roll i tarminflammations-inducerad tumorigenes. Även om K8-/- musens 
tjocktarm inte spontant utvecklar tumörer, var den mycket mer mottaglig för att göra det 
i två tjocktarmscancer-modeller: azoxymetan (eng. azoxymethane, AOM) och multippel 
tarmneoplasi (eng. multiple intestinal neoplasia, ApcMin/+). För att förstå hur avsaknaden 
av keratiner bidrar till uppkomsten av tarminflammations-inducerad tumorigenes, 
undersöktes inflammasomsräckan. Nivåerna av klyvt kaspas-1 och interleukin (IL)-18 var 
höjda i tarmepitelet hos både K8-/- och K8-/-ApcMin/+ möss vilket tyder på att inflammasomen 
var aktiverad. Dessutom sågs en uppreglering av IL-22 och en total förlust av dess negativa 
reglerare IL-22BP i K8-/- musens tarmepitel. Aktiveringen av IL-22 påvisades genom 
förhöjda fosforyleringsnivåer av signal transduktorn och aktivatorn av transkription 
3 (eng. phosphorylated signal transducer and activator of transcription 3, P-STAT3), 
dvs. av transkriptionsfaktorn som reglerar cellproliferering och vävnadsregenerering. 
Målsättningen för det sista delprojektet var att undersöka keratinernas roll i tjocktarmens 
energimetabolism. Genom att kartlägga de största proteinskillnaderna i K8-/- musen, 
jämfört med K8+/+ musens tjocktarmstepitel, identifierades det mitokondriella 3-hydroxy-
3-metylglutaryl-CoA syntas 2 (eng. mitochondrial 3-hydroxy-3-methylglutaryl-CoA 
synthase 2, HMGCS2) som ett nedreglerat protein i K8-/- kolonocyterna. HMGCS2 
reglerar ketogenesen, där bakterie-tillverkad energi i form av korta fettsyror (eng. short 
chain fatty acids, SCFAs) omvandlas till ketonkroppar. Förutom en minskad mängd och 
aktivitetet av enzymet HMGCS2, rapporterades även en lägre nivå av SCFA-transportören 
monokarboxylat transportör 1 (eng. monocarboxylate transporter 1, MCT1), vilket ledde 
till en ökning av SCFAs i avföringen. Sammanfattningsvis visar resultaten från denna 
avhandling att keratiner fungerar som väsentliga reglerare av tjocktarmshomeostasen, 
speciellt när det gäller epitelets differentiering, tjocktarmscancer och engergimetabolismen.
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ABBREVIATIONS
ADAM  A disintegrin and metalloproteinase
AOM Azoxymethane
Apc Adenomatous polyposis coli
ARP-1 Apo A1 regulatory protein-1 
ATP Adenosine triphosphate 
BMPs Bone morphogenic proteins 
CBC Crypt base columnar (cells)
CD Crohn’s disease
CK1 Casein kinase I 
CoA Coactivator
CRC Colorectal cancer
CREB Cyclic AMP-responsive element-binding protein 
CSL  CBF1, Suppressor of Hairless, Lag-1, also known as RBP-J
DC Distal colon
Dhh Desert hedgehog
Dsh Dishevelled 
DSS Dextran sulphate sodium
EMT Epithelial to mesenchymal transition
Eph Ephrin receptor
ER Endoplasmatic reticulum 
FAP Familiar adenomatous polyposis
FLN Full length Notch
Fz Frizzled
GPI Glycosylphosphatidylinositol 
GSK3 Glycogen synthase kinase 3β
HDAC Histone deacetylase 
Hes  Hairy enhancer of split
Hey  Hairy/E(spl)-related with YRPW motif
HMGCS2 3-hydroxy-3-methylglutaryl-CoA synthase, also known as HMG-CoA 
synthase
HNF-4 Hepatocyte nuclear factor 4  
IBD Inflammatory bowel disease 
IFs Intermediate filaments
Ihh Indian hedgehog
8 Abbreviations 
IL Interleukin
IP Immunoprecipitation
K Keratin
LRP Lipoprotein-receptor-related protein 
MAML  Mastermind-like
MCT1 (slc16a1) Monocarboxylate transporter 1
MDBs Mallory-Denk bodies
NHE2, NHE3 Sodium/hydrogen exchanger 2, 3
NICD Notch intracellular domain
NLRP3 NACHT, LRR and PYD domains-containing protein 3
NSP  Nonstarch polysaccharides
P Phosphorylation
PC Proximal colon
Pls1 Plastin 1, also known as fimbrin
PPARα Peroxisome proliferator-activated receptor α 
Ptc Patched (receptor)
PTMs Post-translational modifications
ROS Reactive Oxygen Species
RXR Retinoid X receptor 
S Serine 
SCFAs Short chain fatty acids
SEKs Simple epithelial keratins
Shh Sonic hedgehog  
SMCT (slc5a8) Sodium-coupled monocarboxylate transporter
Sp1 Specificity protein 1 
T  Threonine 
TA Transient-amplifying (cells)
TGF-β Transforming growth factor-beta
TLRs  Toll-like receptors 
TNF Tumor necrosis factor
Ub Ubiquitination
UC Ulcerative colitis
WB Western blotting
Y  Tyrosine 
ZO-1  Zonula occludens-1 
β-cat β-catenin
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INTRODUCTION
The cytoskeleton is a system of filaments present principally in the cytoplasm of eukaryotic 
cells. It consists of three groups: microtubules, microfilaments and intermediate filaments. 
The main role of the cytoskeleton is to support the shape and motility of cells.
Keratins (K) constitute the largest subgroup of intermediate filaments. They are expressed 
in a cell- and tissue-dependent manner and as highly dynamic structures they reorganize 
during cellular events like mitosis and apoptosis. Keratin ability to reorganize is regulated 
by post-translational modifications (PTMs) and keratin-binding proteins. The cell 
and tissue-specific expression pattern of keratins has been used for epithelial tumor 
diagnosis. This feature of keratins also nominates them to serve as a prognostic marker. 
For example, decreased levels of K8 and K20 follow epithelial-to-mesenchymal transition 
(EMT), which facilitates tumor progression in the colon. However, the molecular details 
on how keratins are involved in tumorigenesis remain unknown. 
Mutations in simple epithelial keratins (SEKs) have been associated with liver and skin 
diseases. Although, SEKs are abundantly expressed in the colon, their role remains 
ambiguous. Few studies reported keratin mutations in the patients with inflammatory 
bowel disease (IBD), but further investigation is needed to confirm this link. So far, the 
strongest evidence for keratin involvement in the etiology of IBD comes from the K8 
knock-out (K8-/-) mouse. Apart from the development of chronic colitis, K8-/- colonocytes 
hyperproliferate, are resistant to apoptosis and have mistargeted sodium and chloride ion 
transporters, which results in diarrhea. Antibiotic treatment attenuates the inflammation 
developed by K8-/- colon, which suggests bacteria involvement in the reported phenotypes. 
Bacteria are an integral component of the colon. Bacterial fermentation of carbohydrates 
results in the production of short chain fatty acids (SCFAs), which are used as a source of 
energy by colon epithelial cells and e.g. prevent cancer development.
Colonic epithelium originates from the stem cells, which proliferate and differentiate 
into highly specialized cells. Notch signaling regulates the proliferation of stem cells and 
progenitor cells as well as defines the fate of colonic epithelial cells by orchestrating their 
differentiation. However, the regulators of Notch signaling in the colon remain to be 
defined. 
The aim of this thesis was to investigate the role of keratin intermediate filaments in 
colon homeostasis and disease. The specific areas of the studies included: differentiation 
and proliferation of colonic epithelium, colitis-induced tumorigenesis and colon energy 
metabolism.
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REVIEW OF THE LITERATURE
1. Keratin intermediate filaments
Intermediate filaments (IFs) together with microfilaments and microtubules form the 
cytoskeleton of a cell, providing it with mechanical support and spatial organization 
(Fletcher and Mullins, 2010). IFs constitute a diverse family of proteins encoded by over 
70 genes and are expressed in a cell and tissue specific manner. Each IF protein consists 
of an α-helical rod domain flanked by an N-terminal head and a C-terminal tail (Fig. 1) 
(Pan et al., 2013). Based on the amino acid content in the α-helical rod domain, IFs can 
be grouped into six types presented in Table 1 (Omary, 2009).
1A 2A1B 2BL1 L12 L2
N-terminal
head
C-terminal
tailHighly conserved α-helical rod domain
Figure 1. Tripartite domain structure of IFs. Generally, the IF protein structure is composed 
of an α-helical rod flanked by an amino terminal head and a carboxyl terminal tail. The rod is 
formed by coils 1A, 1B and 2A, 2B separated from each other by linkers L1, L12 and L2. Based on 
this structure IF proteins can form either homopolymers (vimentin) or obligate heteropolymers 
(keratins type I with type II). Based on (Toivola et al., 2005; Eriksson et al., 2009).
Table 1. Classification of IFs.
IF class Components Expression
Type I Acidic keratins Epithelia
Type II Neutral to basic keratins Epithelia
Type III
Desmin
Syncolin Muscles
Peripherin
GFAP
Vimentin
Neurons
Glial cells
Mesenchyma
Type IV
α-Internexin
Neurofilaments 
(NF-L,-M,-H)
Neurons
Nestin
Synemin
Pluripotent cells
Muscle
Type V Lamins(A-, B1-2, C1-, C2) All metazoan cell types
Type VI Bfsp 1Bfsp 2 Lens cell
Created based on The Human Intermediate Filament Database (Szeverenyi et al., 2008). 
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1.1. Keratins and their regulation
Keratins (Ks) are classified as type I (acidic) and type II (neutral to basic) IFs, which form 
heteropolymers with each other in 1:1 ratio. Keratins, as all IFs, are expressed in a cell and 
tissue specific manner, Table 2 (Moll et al., 1982).
Table 2. Classification of keratin IFs.
Keratin types Type I Type II Example of expression
Epithelial  
keratins
K9 – K20
K23 – K24
K1 – K8
K76 – K80
Basal keratinocytes  
(K5/K14)
Simple epithelium of liver  
(K8/K18)
Hair follicle -specific 
epithelial keratins K25 – K28
K71 – K75, 
K80.1
Root sheath
(K25/K71)
Hair/ 
nail keratins K31 – K40 K79 – K86
Hair fiber
K31/K86
Created based on (Moll et al., 2008; Langbein et al., 2010)
The keratins expressed in single layer epithelia are termed simple epithelial keratins 
(SEKs) and are composed of K7-K8, K18-K20 and K23, while keratins expressed in the 
stratified epithelium are known as epidermal keratins or keratinocyte-type keratins and 
consists mainly of K5-K6, K14 and K16 (Omary et al., 2009).
The main role of keratins is cytoprotection from different types of stresses and the 
maintenance of tissue integrity. Apart from this, keratins are involved in processes such 
as protein synthesis and targeting, cell polarity and attenuation of tumor cell migration. 
However, the exact molecular roles of keratins need to be unravel (Omary et al., 2009; 
Pan et al., 2013).
Keratins are functionally regulated by post-translational modifications (PTMs) including: 
phosphorylation, glycosylation, prenylation, acetylation, sumoylation, transamidation 
and caspase cleavage. The PTMs mostly affect the non-conserved head and tail domains of 
keratins regulating their organization, integrity and solubility (Snider and Omary, 2014) 
(Fig. 1). The most common keratin PTM is phosphorylation at the amino acid serine (S), 
threonine (T) and tyrosine (Y). The most abundant is keratin phosphorylation at S: K8 
pS74 (a substrate for p38 and c-Jun N-terminal kinases) (He et al., 2002; Ku et al., 2002a), 
K18 pS34 (phosphorylated by cyclin dependent kinase 2, Cdk2) (Ku et al., 1998) and K18 
pS53 (phosphorylated by protein kinase 2) (Liao et al., 1995). Phosphorylation of S and 
T amino acids makes keratin filaments more soluble, which also affects their dynamics. 
Keratin phosphorylation is believed to act as a phosphate sponge preventing activation 
of pro-apoptotic proteins in liver injury (Ku and Omary, 2006). Moreover, K5, K17 and 
K18 phosphorylation enables these filaments to bind to 14-3-3 protein and be involved 
in cell growth (Liao and Omary, 1996; Kim et al., 2006). Phosphorylation of K8 pS432 is 
also known to influence the migration of cells by decreasing migration of oral squamous 
14 Review of the Literature 
carcinoma cells (Alam et al., 2011a) and increasing migration of gastric and pancreatic 
cells (Busch et al., 2012). The other PTMs affecting keratins is acetylation, e.g. at lysine 
207 of K8 which is increased upon hyperglycaemic conditions when deacetylase SIRT2 
activity is inhibited (Snider et al., 2013). Acetylation at this site is known to decrease 
filament solubility and promote filament formation (Snider et al., 2013; Snider and 
Omary, 2014). Acetylation of keratins has been suggested to be promoted by short chain 
fatty acids (SCFAs) in colon cancer cell lines studies (Leech et al., 2008) since SCFAs are 
inhibitors of deacetylases (Gibson et al., 1999). 
Another regulatory mechanism of SEK functions is via their interaction with various 
keratin-associated proteins. Keratin filaments bind to the desmoplakin, a protein present 
in desmosomes in the lateral parts of the cell (Alberts et al., 2015) and thus provide 
tissues with mechanical strength (Delva et al., 2009). In the apical part of the cells and 
also in the region of desmosomes, keratins bind trichoplein protein (Nishizawa et al., 
2005). The best studied keratin interaction so far, is the binding of keratin to the 14-3-3 
scaffold protein. K18 pS33 binds 14-3-3 during mitosis (Ku et al., 1998) and K17 T9/S44 
during wound healing (Kim et al., 2006). Proteins binding keratins also connect them to 
the other cytoskeletal components. A protein which links keratins with microfilaments is 
plastin 1 (Pls1), a major actin bundling protein, which interacts with K19 (Grimm-Gunter 
et al., 2009). Keratins are also connected to microtubules via binding to phosphorylated 
γ-tubulin complex protein GCP6 (Oriolo et al., 2007). In addition, there is an evidence for 
keratin-nuclear protein interaction, which comes from keratin binding to plectin (Suozzi 
et al., 2012). Plectin also connects with the nesprin-3, which is an outer nuclear envelope 
protein. Deletion of nesprin-3 in Zebra fish has demonstrated diminished amount of 
keratins around the nucleus (Postel et al.; Postel et al., 2011). Recent studies also show K17 
colocalization with autoimmune transcription factor Aire in the nucleus of epidermoid 
carcinoma cells (Hobbs et al., 2015). Many of the described keratin-associated proteins 
were found in the colon, which suggests the regulatory role of keratins in this organ.
1.2. Keratin associated diseases
Keratin mutations are associated with certain diseases (Toivola et al., 2015b). Mutations 
in stratified epithelium keratins lead to numerous skin diseases, e.g.: epidermolysis 
bullosa simplex (mutations in K5 and K14) (Bonifas et al., 1991; Coulombe et al., 1991; 
Lane et al., 1992) and hyperkeratosis (mutations in K1 or K10) (Syder et al., 1994) . 
Mutations in SEKs have been reported to predispose to liver diseases. Around 12% of 
patients with liver diseases carry K8/K18 mutations (Omary, 2009). The main diseases, to 
which K8 and K18 mutations predispose, are: acute liver failure and chronic liver disease 
(Strnad et al., 2010). Moreover, mutations in K8 and K19 can lead to primary biliary cirrhosis 
(Omary, 2009; Omary et al., 2009). Although, SEKs are expressed in both the endocrine and 
exocrine pancreas, there are no clear evidences for keratin mutation causing diseases in this 
organ (Cavestro et al., 2003). Nevertheless, the loss of K8 in mice leads to decreased insulin 
production and increased susceptibility to develop diabetes (Alam et al. 2013).
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So far mutations in K7, K20 or K23 in human diseases have not been reported (Omary 
et al., 2009). K7 knock-out (K7-/-) mice display only minor changes in the proliferation 
of bladder urothelial cells and altered expression of K7 partners: K18 downregulation 
and K20 upregulation (Sandilands et al., 2013). K7 and K20 are often used as markers 
of colorectal cancers, in which they exhibit decreased and increased expression, 
respectively (Karantza, 2011). Moreover, increased levels of phosphorylated K23 form 
are detected in colon adenocarcinomas (Birkenkamp-Demtroder et al., 2007). Keratin 
expression is also known to decrease in the process of epithelial to mesenchymal 
transition (EMT), which occurs e.g. during cancer invasion and metastasis (Kalluri 
and Weinberg, 2009). K8 and K20 show decreased expression during EMT of colorectal 
tumors (Knosel et al., 2006).
1.3. Keratin expression and role in the colon
K8 and its partners K18 and K19 are the main SEKs expressed in colonic epithelium 
(Fig. 2). There are also expressed K7 and K20 in smaller amounts (Zhou et al., 2003). 
Although, increased levels of K23 were reported in colon adenocarcinomas (Birkenkamp-
Demtroder et al., 2007) it remains unknown whether it is expressed under the basal 
conditions in colonic epithelium.
K7 K8 K18 K19 K20
X
X
X
K23*
?
Legend: goblet cells X enteroendocrine cells 
Crypt 
tip
Crypt 
base
X
X
X
COLONIC KERATIN IFs
Colonic crypts
Type II Type I
Figure 2. Schematic distribution of keratins in the colonic crypts. K8 displays the highest 
expression pattern and its partners K18 and K19. The other type II keratin, K7 is expressed at a 
very low level, including in the goblet cells. The levels of K18 and K19 in the colon are similar. 
K20 is distributed in the upper portion of crypts and in enteroendocrine cells. Note, most Ks are 
expressed in goblet cells but not specified in the figure. *The expression and distribution of K23 in 
the colon remains to be studied. Adapted from (Zhou et al., 2003).
The main role of keratins in the colon is to maintain tissue integrity and protect from 
different types of stresses (Ameen et al., 2001; Haines and Lane, 2012; Pan et al., 2013). 
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However, the exact role of keratins in colon health remains unclear. The key evidence 
for keratin involvement in the colon health comes from the K8 knock-out (K8-/-) mouse 
model (Baribault et al., 1994). K8-/- mouse colon displays T helper cell 2 (Th2)-type early 
chronic inflammation resembling human ulcerative colitis, crypt hyperproliferation 
and resistance to apoptosis (Habtezion et al. 2005; Habtezion et al., 2011). Moreover, 
mistargeted sodium and chloride ion transporters at the apical membrane of K8-/- 
ileum and colon lead to diarrhea in these mice and highlights the role of keratins in 
protein targeting (Toivola et al., 2004). The decreased amount of keratins increases 
the susceptibility to experimental colitis, as shown on K8 heterozygote (K8+/-) mice 
(Asghar et al., 2015a)
Apart from the K8-/- and K8+/- model, few studies showing human keratin mutations 
in inflammatory bowel disease (IBD) have been published so far (Buning et al., 2004; 
Owens et al., 2004; Tao et al., 2007), although they do not indicate a strong link 
between these two. However, in human colitis the decreased levels of K8, K18-19 
and changes in K8 phosphorylation have been observed (Corfe et al., 2015a). An 
interesting study revealed that interleukin (IL)-6 can induce the expression of colonic 
K8 and K18, which contributes to the maintenance of the colonic barrier (Wang et 
al., 2007). As mentioned earlier, keratin filaments are posttranslationally modified. 
K8 was found to be a substrate for Ubc9 enzyme, which regulates the sumoylation 
of filaments in the small intestine (Demarque et al., 2011) and contributes to the 
mechanical stability. Proteomic analysis revealed K8 to be highly acetylated in 
colon cancer cell lines (Leech et al., 2008), which is likely linked to the levels of the 
deacetylase inhibitor - butyrate. The study from the same research group suggested 
that butyrate can decrease the levels of K8 expressed in colon tumors (Khan et al., 
2011). However, the mechanism and importance of these changes remain unclear. 
Increased levels of phosphorylated K23 have been observed in microsatellite-stable 
colon tumors, which distinguishes them from the microsatellite-instable tumors 
(Birkenkamp-Demtroder et al., 2007). 
Several studies indicated binding partners of keratins in the colon or small intestine. One 
of the keratin-binding protein is the previously mentioned trichoplein, which by binding 
to K8/K18 may regulate filament organization at the apical part of the cell (Nishizawa 
et al., 2005). The binding of Albatross protein to the K8/K18 is essential for Caco-2 cell 
polarity. The knockdown of the Albatross results in keratin filament reorganization and 
loss of apical junctional complex proteins (Sugimoto et al., 2008). K19 is bound by plastin 
1 (fimbrin) protein in the small intestine, which help in the organization of the terminal 
web. Interestingly, the same study showed that the loss of plastin 1 in mice makes them 
more susceptible to induced-colitis (Grimm-Gunter et al., 2009). A crucial role for 
establishing an apico-basal polarity has atypical protein kinase C (aPKC) (Suzuki and 
Ohno, 2006). Its levels are strongly decreased in K8-/- colon (Mashukova et al., 2009) as 
well as in IBD patients (Wald et al., 2011). Recent studies have shown that keratin-Hsp70 
chaperoning of aPKC is regulated by BAG protein during inflammation (Mashukova et 
al., 2014).
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2. Colon
Colon (large intestine) together with small intestine constitute the lower parts of the 
gastrointestinal tract. Anatomically the human colon is subdivided into four parts: 
ascending, transverse, descending and sigmoid. The ascending and transverse colon form 
the proximal colon (PC), while the descending and sigmoid form the distal colon (DC) 
(Ross, 2011). The main role of the colon is to pass undigested food and reabsorb water, 
sodium ions and water-soluble vitamins. The large intestine is also a place inhabited by 
microbiota which stimulate the immune system and produce SCFAs essential for colon 
homeostasis (Tan et al., 2014).
2.1. Colon epithelial cells
The colon consists of several tissue types (Fig. 3). The most inner part of the colon is a 
single layer of epithelial cells (simple epithelium), which together with the lamina propria 
and muscularis mucosae form the mucosa (Johnston, 2000). 
Figure 3. Tissue layers of the colon. Epithelial cells are the most inner cells exposed to the lumen 
of the colon and together with the lamina propria and the muscularis mucosae form the mucosa. 
The following tissue layers beneath the mucosa are: submucosa, muscularis externa, subserosa 
and serosa. Adapted from (Johnston, 2000).
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Epithelial cells form invaginations in the colonic mucosa called crypts (Fig. 2-4) and 
are the fastest renewing cells in the whole body (Schepers and Clevers, 2012). The 
process of renewal takes 3-5 days and is stimulated by multipotent stem cells crypt 
base columnar (CBC) and +4 stem cells located in the bottom of the crypts (Fig. 4) 
(Medema and Vermeulen, 2011; Krausova and Korinek, 2014). Stem cells self-renew 
and give rise to proliferative progenitor cells called transient-amplifying (TA) cells, 
which can next differentiate into absorptive enterocytes, enteroendocrine cells, goblet 
cells and tuft cells. Enterocyte cells are mainly responsible for absorption of ions, 
water and vitamin B12 in the colon. Enteroendocrine cells are secretory cells releasing 
different types of hormones mainly serotonine and somatostatin, which regulate 
colonic motility and peristalsis (Gunawardene et al., 2011). Goblet cells are a very 
abundant cell type in the distal part of the colon, where they produce mucus, a lubricant 
protecting from bacterial adhesion and epithelium abrasion caused by passing stool 
(Corazziari, 2009). Tuft cells constitute the smallest population of epithelial cells in 
the colon and their exact role remains ambiguous. Nevertheless, some data suggests 
the involvement of tuft cells in intestinal smooth muscle contraction and absorption 
of fatty acids (Gerbe et al., 2012). The processes of colon epithelial cell proliferation 
and differentiation are tightly controlled by several signaling pathways, mainly Wnt 
and Notch signaling. Differentiated epithelial cells die by the apoptosis occurring on 
the top of the crypt. 
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Figure 4. Colon crypt with epithelial cells. Stem cells crypt base columnar (CBC) and +4 
cells give rise to transient amplifying (TA) cells, which proliferate and then differentiate 
into absorptive enterocytes or secretory enteroendocrine cells, goblet cells and tuft cells. 
Differentiated cells die of apoptosis on the top of the crypt. Adapted from (Varedi et al., 2001; 
Sancho et al., 2015).
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2.2. Maintenance of colon cell homeostasis: proliferation and 
differentiation
Epithelial cell proliferation, differentiation, migration and apoptosis are processes 
involved in colon homeostasis. The Wnt/β-catenin signaling pathway together with 
Hedgehog, transforming growth factor beta (TGF-β) and bone morphogenetic 
protein (BMP) pathways regulate proliferation. The Notch signaling pathway controls 
both proliferation and differentiation of the colonic cells, while the role of Eph/Ephrin 
pathway is to maintain cell contact and facilitate cell migration within the colonic 
crypt.
2.2.1. Wnt/β-catenin pathway
Wnt/β-catenin pathway (the canonical Wnt pathway) is a contact-dependent signaling, 
in which the proteolysis of β-catenin (β-cat) is regulated. In the colon, the Wnt/β-cat 
pathway is mostly active in the bottom of the crypt, where transmembrane receptor 
Frizzled (Fz) and low-density lipoprotein-receptor-related protein (LRP) are bound 
to the Wnt ligand proteins. Receptor activation leads to the binding of Dishevelled 
(Dsh) and Axin proteins to Fz and LRP, respectively. Axin binding to LRP is regulated 
by phosphorylation through casein kinase I (CK1) and glycogen synthase kinase 
3β (GSK3). Axin and Dsh are in the complex with these kinases as well as tumor 
suppressor protein adenomatous polyposis coli (Apc) and β-cat in the cytoplasm. 
The complex they form is also called the destruction complex. When there is no Wnt 
ligand, CK1 and GSK3 kinases phosphorylate β-cat, which is next ubiquitinated by 
β-TrCP and degraded in the proteasome. Proteasomal degradation of β-cat prevents 
its nuclear translocation and activation of target genes (Fig. 5A). β-cat degradation 
is inhibited when Wnt ligands are present. Next, β-cat translocates to the nucleus 
and binds to LEF1/TCF transcription factors, which results in Wnt target gene 
transcription, mainly Axin2, c-Myc and Lgr5 (Fig. 5B) (Clevers and Nusse, 2012; 
Alberts et al., 2015). 
The Lgr5 gene has been discovered as a marker of stem cells in both small and large 
intestine (Barker et al., 2007). Since Wnt signaling is important for colonic stem cell 
amplification, mutations in this pathway leads to the colorectal cancer. Most common 
mutations in the Wnt pathway occur in the APC gene. Germline mutations in APC lead 
to hereditary colorectal cancer called familiar adenomatous polyposis (FAP) (Nishisho et 
al., 1991), (Kinzler et al., 1991). A total loss of Apc alleles is observed in many sporadic 
cases of colorectal cancer. In both cases of colorectal cancer, β-cat cannot be stabilized 
and constitutively binds to the TCF activator of transcription in the colon, Tcf4 (Korinek 
et al., 1997). Constitutively active Axin2 upregulates Snail1, which results in EMT in the 
colon tissue (Wu et al., 2012), while Myc overexpression stimulates hyperproliferation 
and uncontrolled cell growth (Alberts et al., 2015). 
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Figure 5. The Wnt/β-catenin pathway. A. When the Wnt ligand (WNT) is absent, β-catenin 
(β-cat) is constantly phosphorylated by the destruction complex and ubiquitinated by 
β-TrCP, which marks it for the degradation by the proteasome. B. In the presence of Wnt 
ligand, the destruction complex binds phosphorylated LRP. Phosphorylation of β-cat is 
maintained; however, its ubiquitination is blocked. This leads to the accumulation of β-cat in 
the cytoplasm and its translocation to the nucleus, where β-cat replaces Groucho (repressor of 
transcription) and causes transcription of genes responsible for cell proliferation and growth. 
P = phosphorylation, Ub = ubiquitination. Adapted from (Clevers and Nusse, 2012; Alberts et 
al., 2015).
There are also non-canonical Wnt pathways: the planar polarity pathway and the 
Wnt/calcium pathway. The planar polarity pathway is dependent on the GTPases 
Rho and defines the polarization of epithelial cells during development (Alberts et 
al., 2015), while the Wnt/calcium pathway relays on PLC or PDE proteins, which 
by binding Dsh, can either cause calcium release from endoplasmatic reticulum 
(ER) (binding to PLC) or calcium release inhibition (binding to PDE), (Komiya and 
Habas, 2008). 
β-cat, apart from being a part of Wnt signaling pathway, is a binding partner of E-cadherin 
in adherens junctions of the simple epithelia (Peifer et al., 1992), where it helps to bind to 
the actin filaments and is, thus, involved in the response to tensions in the cell (Alberts 
et al., 2015).
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2.2.2. Notch pathway
The Notch pathway regulates the proliferation of colonic stem cells and progenitor 
cells and defines cell fate by influencing the differentiation of transient amplifying 
cells (Fre et al., 2005). Notch signaling is a contact-dependent pathway. Notch 
heterodimeric transmembrane receptor (isoforms Notch 1-4) is located on the cell 
membrane of one cell (signal-receiving cell) and the Notch ligand (Jagged 1–2 or 
Delta-like proteins 1, 3 and 4) is present on the cell membrane of other cell (signal-
sending cell) (Kopan and Ilagan, 2009). Both Notch ligands and Notch receptors are 
expressed in the colonic epithelial cells (Reichrath J. and S., 2012). The interaction 
between Notch and Delta leads to a lateral inhibition, a phenomenon in which one 
differentiating cell inhibits the simultaneous differentiation of a neighboring cell 
(Alberts et al., 2015). 
In the canonical Notch pathway, ligand binding to the FLN (Full Length Notch) 
causes a cleavage of Notch extracellular domain by ADAM (A Disintegrin And 
Metalloproteinase) and next the intracellular domain is cleaved by γ-secretase (Fig. 6). 
A single cleavage by ADAM leads to a generation of ΔE Notch, while the subsequent 
γ-secretase creates a truncated form of Notch called NICD (Notch Intracellular 
Domain). NICD stability is regulated by E3 ubiquitin ligases (Kopan and Ilagan, 2009). 
NICD translocates to the nucleus, where it binds to the transcription factor CSL (CBF1, 
Suppressor of Hairless, Lag-1) together with MAML (mastermind-like) and other 
coactivators, and acts as a transcription factor inducing the transcription of Hes (hairy 
enhancer of split) and Hey (Hairy/E(spl)-related with YRPW motif) genes (Sancho et 
al., 2015). These genes initiate a genetic program, which determines the proliferation 
of stem cells and progenitor cells as well as differentiation of TA cells into absorptive 
enterocyte cells. Hes blocks the transcription factor Atoh1 (Math1) which in the lack of 
NICD determine a secretory fate of the cells in the intestine (High and Epstein, 2008; 
Sancho et al., 2015) (Fig. 6). 
The Notch pathway is also regulated via non-canonical mechanism, which might be 
independent from the ligand and CSL. The best studied Notch non-canonical pathway 
is the regulation of Wnt/β-cat, in which Notch can directly or indirectly bind to β-cat 
in stem cells and progenitor cells leading to lysosomal β-cat degradation (Kwon et al., 
2011). 
Notch can either act as a tumor suppressor or an oncogene depending on the context 
(Reedijk et al., 2008; Lobry et al., 2011; Sonoshita et al., 2015). In colon cancer, Notch 
is mostly known as an oncogene (Ghaleb et al., 2008; Miyaki et al., 2009; Rodilla et al., 
2009), although one study shows that deletion of Notch1 leads to colon tumorigenesis in 
mice (Liu et al. 2011). 
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Figure 6. The Notch signaling pathway determines cell fate in the colonic crypt. Notch 
signaling is active when one of the ligands (Jagged or Delta) on the signal-sending cell binds to 
the FLN (Full Length Notch) present on the signal-receiving cell. This interaction causes FLN 
cleavage into NICD (Notch Intracellular Domain) by ADAM and γ-secretase. NICD translocates 
to the nucleus and binds to the CSL protein, other coactivators (CoA) and MAML, which together 
induce transcription of Hes and Hey genes. Hes and Hey stimulate the proliferation of stem cells 
and progenitor cells as well as differentiation of TA cells into absorptive enterocytes. Because 
Hes and Hey block the Atoh1 transcriptional factor, no differentiation of TA cells into secretory 
lineage occurs. The scheme does not present the first cleavage of Notch receptor into a mature 
heterodimeric form of FLN, which happens in the Golgi lumen prior Notch transport to plasma 
membrane. Based on (High and Epstein, 2008; Guruharsha et al., 2012; Sancho et al., 2015).
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2.2.3. TGF-β/BMP, Hedgehog, Hippo and Eph/Ephrin pathways
BMPs are expressed by the mesenchymal cells in the colon. TGF-β/BMP pathway inhibits 
Wnt signaling and stimulates differentiation in the intestine (Medema and Vermeulen, 
2011). This stimulation is mediated via SMAD transcriptional activator (Brazil et al., 
2015).
Hedgehog signaling involves the hedgehog protein (Hh) and its receptor Patched (Ptc), 
which activates the transcription factors GLI1-3. Hh is encoded by three different genes 
in the mammalians: Sonic (Shh), Desert (Dhh) and Indian (Ihh) (Alberts et al., 2015). 
Ihh is the main type of Hh in the colon, which regulates the differentiation of enterocytes. 
On the other hand, the Ptc receptor is expressed by the mesenchymal cells, which suggest 
the Hedgehog pathway to signal from the epithelium to the mesenchyme (van den Brink, 
2007).
Hippo signaling regulates the growth of the cells by inhibiting apoptosis and 
proliferation thus it is an antagonist of Wnt pathway. The main effectors of the Hippo 
pathway are the Yap/Taz proteins, which bind Tead1-4 transcription factor in the 
nucleus. Yap/Taz proteins can also bind proteins of tight and adherens junctions (Jeon 
et al., 2013; Yu et al., 2015). In the dextran sulfate sodium (DSS)-treated colon, Hippo 
signaling is known to stimulate regeneration of the cells by upregulating Yap levels 
(Cai et al., 2010).
Eph/Ephrins belong to the receptor tyrosine kinase (RTK) family. Eph receptor 
is a transmembrane protein, which is activated upon binding to its ligand - 
ephrins. There are two types of ephrins: ephrins A, attached to the membrane by a 
glycosylphosphatidylinositol (GPI) and ephrins B, which are transmembrane proteins. 
EphA receptors bind ephrins A, while EphB receptors interact with ephrins B. The 
role of the Eph/Ephrin signaling in the colon, is to maintain cell-cell contact and cell 
migration (Park and Lee, 2015). It is known that EphB/EphrinB expression is regulated 
by the Wnt pathway (Batlle et al., 2002).
2.3. Energy metabolism of the colon
The human colon is colonised by an enormous amount of bacteria. They protect from 
pathogen invasion and regulate immune responses. Due to bacterial ability to ferment 
undigested carbohydrates, they also contribute to the energy metabolism of epithelial 
cells. 
2.3.1. SCFA production and absorption
Short chain fatty acids (SCFAs) are a group of saturated, either branched or unbranched 
monocarboxylic acids. Apart from one carboxyl group (-COOH), they consist of 2-6 
carbon atoms in their chains (Table 3).
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Table 3. Classification and chemical formulas of main SCFAs present in the colon.
Name Chemical Formula Type / % in the colon 
Acetate CH3-COOH Unbranched
90-95%Propionate CH3-CH2-COOH
Butyrate CH3-(CH2)2-COOH
Isobutyrate
CH3-CH-COOH
CH3 Branched
5-10%
Isovalerate
CH3-CH-CH2-COOH
CH3
SCFAs, mainly acetate, propionate and butyrate, are produced in the process of 
bacterial fermentation. Microbiota residing in the colon ferment mostly dietary fiber in 
the proximal colon (Fig. 7), which can be described by a chemical reaction as: 
59 C6H12O6 + 38 H2O → 60 CH3COOH + 22 CH3CH2COOH + 18 CH3CH2CH2COOH + 
96 CO2 + 268 H+ + heat + additional bacteria (Topping and Clifton, 2001).
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Figure 7. Transit, digestion and fermentation of the food by the gastrointestinal tract. 
Comminuted food is digested in the small intestine by the intrinsic enzymes. Undigested and 
unabsorbed elements like starch, nonstarch polysaccharides (NSP, mainly dietary fiber) are moved 
to the large intestine. The fermentation is primarily conducted by bacteria in the proximal colon, 
thus produced and absorbed SCFA amounts are the greatest there. Adapted from (Topping and 
Clifton, 2001).
SCFAs are absorbed and used as a source of energy by colon epithelial cells (Havenaar, 
2011). There are two ways by which SCFA are transported through the membrane of 
epithelial cells. The protonated pool of SCFAs (Cx-COOH, 0.1 – 5% of the whole SCFA 
pool), which is lipid soluble, is transported through the cell membrane by diffusion. 
The diffusion can be supported by sodium/hydrogen exchangers NHE2 and NHE3 
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expressed in the apical membrane of the cells (Fig. 8) (Krishnan et al., 2003; Guan 
et al., 2006). However, most of the luminal SCFAs is in the ionized form (Cx-COO-) 
and requires active transport via special transporters. The most common SCFA 
transporters expressed by epithelial cells are: monocarboxylate transporter 1 (MCT1, 
slc16a1) and sodium-coupled monocarboxylate transporter (SMCT, slc5a8) (Fig. 8). 
MCT1 and SMCT apart from SCFA, also transport pyruvate and lactate (Ritzhaupt et 
al., 1998).
MCT1 is a membrane protein bound in a complex with a glycoprotein basigin (CD147) 
(Kirk et al., 2000). Both MCT1 and basigin levels can be upregulated by somatostatin in 
the colon resulting in a higher uptake of butyrate (Saksena et al., 2009). Recent studies 
have showed that G protein coupled receptor GPR109A is activated by SCFAs (Thangaraju 
et al., 2009) and mediates the MCT1 targeting on the apical membrane of the colonocytes 
(Borthakur et al., 2012). The levels of MCT1 mRNA can also be increased by butyrate 
(Cuff et al., 2002) and transcription factor peroxisome proliferator-activated receptor 
alpha (PPARα) (Konig et al., 2008). 
SMCT is also a plasma membrane transporter of SCFA and it is expressed on the apical 
membrane of the colonocytes (Gopal et al., 2007). SMCT is known as a tumor suppressor 
due to its function to transport butyrate, which acts as a histone deacetylase (HDAC) 
inhibitor and leads to apoptosis of cancer cells (Thangaraju et al., 2008).
2.3.2. Ketogenesis
Butyrate is the most essential SCFA absorbed since it is used as a fuel by colonocytes. 
After the uptake, butyrate is transported into the mitochondria of the colon epithelial 
cells, while acetate and propionate are transported to the liver. Colonocytes spend 70% 
of their oxygen resources into the butyrate oxidation, in which acetyl-CoA is produced. 
Acetyl-coA is next used in the Krebs cycle or in ketogenesis (Fig. 8). Although the main 
organ of ketogenesis is the liver, ketone body production also occurs in the colon and 
kidneys. (Hegardt, 1999)
Ketogenesis consists of four enzymatic reactions, during which acetyl-coA is converted 
into ketone bodies: acetoacetate, acetate, and β-hydroxybutyrate. In the first step, two 
molecules of acetyl-CoA are condensed into acetoacetyl-CoA, to which in the next step, 
another acetyl-CoA is added by 3-hydroxy-3-methylglutaryl-CoA synthase (HMG-CoA 
synthase, HMGCS2). The intermediate HMG-CoA is produced, which is then converted 
by HMG-CoA lyase into acetoacetate. Acetoacetate can be transformed either into 
acetone in the non-enzymatic reaction or into β-hydroxybutyrate by β-hydroxybutyrate 
dehydrogenase (Fig. 8). 
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Figure 8. Transport of SCFA and their utilization during ketogenesis to produce ketone bodies. 
SCFA are absorbed into epithelial cells by diffusion (protonated form Cx-COOH) using NHE2/3 
exchangers or mostly by active transport (the ionized form Cx-COO-) using SMCT and MCT1 
transporters. After absorption, SCFA are transported to the mitochondria where they are oxidized 
into acetyl-CoA. Acetyl-CoA is either used for the production of ATP in the Krebs cycle or enter 
the ketogenic pathway. Ketogenesis consists of 4 steps in which ketone bodies acetoacetate, acetone 
and β-hydroxybutyrate, are produced. The rate-limiting enzyme of ketogenesis is HMGCS2 
(marked in red). Based on (Hegardt, 1999).
HMGCS2 is the rate-limiting enzyme of the ketogenic pathway, since only this enzyme 
activity is lower when the ketogenesis level is decreased. The HMGCS2 enzyme activity 
corresponds with its transcription and protein expression (Hegardt, 1999). HMGCS2 
transcription is regulated by physiological conditions such as starvation, diabetes or 
prolonged exercise. To the molecules which are responsible for activation of HMGCS2 
transcription belong: cyclic AMP-responsive element-binding protein (CREB), specificity 
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protein 1 (Sp1) and the most prominent – the transcription factor peroxisome proliferator-
activated receptor α (PPARα). PPARα mediates the transcription of HMGCS2 in response 
to SCFA availability, thus the lack of bacteria or dietary fiber correlates with decreased 
expression of HMGCS2. PPARα upon SCFA activation binds to the promotor sequence 
PPRE and as an obligatory heterodimer with retinoid X receptor (RXR) activates the 
transcription of HMGCS2. Interestingly, HMGCS2 itself serves as a ligand for PPARα, 
which enables HMGCS2 to regulate its own expression. Studies with PPARα wild-type 
and knock-out mice have shown that PPARα can also regulate the transcription of MCT1 
in liver, kidney and small intestine (Konig et al., 2008). HMGCS2 activity is repressed by 
c-myc, hepatocyte nuclear factor 4 (HNF-4), apo A1 regulatory protein-1 (ARP-1) and 
insulin (Hegardt, 1999).
Ketone bodies are used as a source of energy in colon or are transported to the organs 
requiring energy, like brain or muscles. The uptake of ketone bodies is possible by 
monocarboxylate transporters (MCTs) expressed in the cell membranes. Next, ketone 
bodies are transported to the mitochondria, where they are transformed to acetyl-CoA, 
which enters Krebs cycle and the energy in a form of adenosine triphosphate (ATP) is 
produced. (Hegardt, 1999)
2.3.3. The role of butyrate for colonic health
Butyrate not only serves as a fuel for colonocytes, but extensive studies have revealed 
an inhibitory role of butyrate to colitis and colorectal cancer. The most common 
effects of butyrate observed in tumor cell lines are the inhibition of proliferation and 
induction of apoptosis (Hodin et al., 1996; Comalada et al., 2006). Apart from this, 
butyrate is believed to shift the differentiation pattern of the colonic epithelium cells 
from secretory to absorptive type by Muc2 repression (Augenlicht et al., 2003). The 
molecular mechanism behind butyrate action is the ability to regulate gene expression. 
Butyrate acts as an inhibitor of enzyme histone deacetylase (HDAC), which prevents 
chromatin condensation and makes DNA more accessible for transcriptional factors 
(Hinnebusch et al., 2002; Sekhavat et al., 2007). Butyrate can affect the defense barrier 
and permeability of the intestine by increasing the expression of glycoproteins and 
trefoil factors (Hamer et al., 2008). The anti-inflammatory effects of butyrate to colonic 
mucosa are mainly mediated by the inhibition of nuclear factor kappa B (NF-κB), 
which is often dysregulated in colitis (Inan et al., 2000; Yin et al., 2001). Moreover, 
butyrate regulates the differentiation of immune cells (Furusawa et al., 2013) and their 
function (Chang et al., 2014). The anti-carcinogenic properties of butyrate result from 
its ability to decrease plasmin activation (a protease involved in cancer invasion and 
metastasis), inhibit angiogenesis related proteins (VEGF and HIF-1α) and activate 
glutathione-S-transferases (GSTs, enzymes detoxifying carcinogens) (Antalis and 
Reeder, 1995; Ebert et al., 2001; Zgouras et al., 2003; Yu et al., 2010). The effect of 
butyrate on K8 expression in the colorectal cancer has also been studied. A proteomic 
analysis of human colorectal cancer cells (HCT116) revealed high acetylation of K8 
upon butyrate treatment, which led to decrease in filament solubility (Leech et al., 
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2008). However, two in vivo studies on human CRC, showed contradictory results on 
how butyrate affects the K8 expression in tumor tissue (Khan et al., 2011; Evans et al., 
2015).
2.4. Diseases affecting colon
2.4.1. Inflammatory Bowel Disease (IBD)
Inflammation is a protective response of vascularized tissues to infection and tissue damage. 
The main components of inflammatory responses are blood vessels and leukocytes. They 
respond to the inflammatory stimuli such as microbial infections or tissue necrosis. The 
process of inflammatory response is multistep and can be roughly divided into five phases: 
recognition of the inflammatory stimulus, leukocyte recruitment, injurious agent removal, 
response control and repair. Cells are able to recognize invading microbiota by receptors 
expressed in the plasma membrane, cytoplasm or endosomes with the best characterized 
Toll-like receptors (TLRs). Moreover, cells express receptors in their cytoplasm, which 
can sense cell damage, e.g. DNA damage (uric acid release), mitochondria damage (ATP 
release) or cell membrane damage (potassium ion decrease). These receptors, upon cell 
damage, activate inflammasomes (see more detailed information in paragraph 2.4.1.3), 
which are multiprotein complexes present in the cytoplasm. Inflammasomes trigger 
the immune response by activating interleukins (IL)-1 and IL-18, which in turn recruit 
leukocytes. Leukocytes also express receptors, which recognize Fc parts of antibodies 
present on the microbes, and lead to the destruction of the invader. Leukocytes remove 
the microbes and dead cells by phagocytosis, a process in which microbes are engulfed 
into phagolysosomes and destroyed by reactive oxygen species (ROS), nitric oxide (NO) 
and lysosomal enzymes. There are several mediators of inflammation, which initiate 
and control the inflammatory response. Foremost mediators are: cytokines, vasoactive 
amines and lipid products. The anti-inflammatory mediators including lipoxins and 
the cytokines: IL-10 and TGF-β inhibit the inflammatory response when not needed 
anymore. However, when the cause of inflammation cannot be eliminated, it might lead 
to a chronic inflammation such as inflammatory bowel disease (IBD). (Vinay Kumar, 
2015) 
IBD is a chronic inflammation of multifactorial etiology including genetic susceptibility, 
microbial flora, dysregulated immune system and environmental factors. Diseases 
considered as IBDs are Crohn’s disease (CD) and ulcerative colitis (UC), which 
together affect around 5 million people worldwide (Chrohn’s and Colitis Fundation 
of America). The major difference between CD and UC relates to the affected region 
of bowel and inflammation range. CD can affect both ileum and colon, while UC is 
present only in the colon region. The range of inflammation is also wider in the CD, 
since it can be transmural compared to the exclusively affected mucosal area in UC. To 
the most common symptoms of IBD belong diarrhea, abdominal pain and fever (Vinay 
Kumar, 2015). 
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2.4.1.1. Risk factors for developing IBD
Genetic factors. Up to year 2012, genetic studies have identified 163 risk-conferring loci 
for IBD, from which 110 loci overlap for CD and UC risk, 30 loci are exclusive for CD 
and 23 for UC incidence (Jostins et al., 2012). Most of the loci common for UC and CD 
are associated with the immune system and examples of genetic risk factors are presented 
in Table 4. 
Table 4. Examples of genetic risk factors for developing IBD.
Gene Protein function; putative changes in IBD
Susceptibility to
References
CD UC
NOD2 
(CARD15)
intracellular receptor, microbial 
peptidoglycan detection and  
NF-κB signaling activation; 
dysfunction of intestinal barrier
 
(Hugot et al., 2001)
(Ogura et al., 2001)
(Philpott et al., 2014)
CARD9
scaffold protein, MAPK and NF-κB 
signaling activation; dysfunction of 
intestinal barrier
  (Rivas et al., 2011)(Beaudoin et al., 2013)
NLRP3
scaffold protein, IL-1β and  
IL-18 maturation; deregulation of IL-
1β and IL-18 synthesis
  (Villani et al., 2009)
IL10 and 
IL10R
inhibition of innate and adaptive 
immunity; impaired inflammatory 
response to bacteria
 
(Kucharzik et al., 1995) 
(Glocker et al., 2009)
(Kotlarz et al., 2012)
JAK2/STAT3
signal transmission from cytokines 
to nucleus; dysfunction of intestinal 
barrier, alterations in T cell activation
 
(Barrett et al., 2008)
(Polgar et al., 2012)
(Basso et al., 2014)
IRGM GTP-binding protein, autophagy induction; dysfunction of autophagy  
(Palomino-Morales  
et al., 2009)
ATG16L1
protein involved in 
preautophagosomal complex 
formation; impaired autophagosome 
formation
  (Palomino-Morales  et al., 2009)
ITLN1
microbial galactofuranosyl 
recognition and binding; dysfunction 
of intestinal barrier
  (Barrett et al., 2008)
 susceptible,  unsusceptible. Abbreviations: nucleotide-binding oligomerization domain 2 
(NOD2), caspase recruitment domain-containing protein 15 (CARD15), nuclear factor Kappa-B 
(NF-κB), mitogen-activated protein kinases (MAPK), interleukin 10 (IL-10), interleukin 10 
receptor (IL-10R), Janus kinase 2 (JAK2), signal transducer and activator of transcription 3 
(STAT3), immunity-related GTPase family M protein (IRGM), autophagy related 16-Like 1 
(ATG16L1), intelectin 1 (ITLN1).
Interestingly, missense mutations in K8 (KRT8) and a polymorphism of K19 gene (KRT19) 
have been detected in IBD patients (Owens et al., 2004). In vitro studies revealed impaired 
filament assembly as well as disruptions in intestinal barrier in disease-associated keratin 
mutations (Zupancic et al., 2014). Although different variants of KRT8 and KRT19 are 
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present in spontaneous cases of IBD, so far they have not been linked to the familial IBD 
(Tao et al., 2007).
Microbial flora. Microbial flora is another factor essential for the pathogenesis of IBD. 
Most studies profiling microbiota in the IBD gut show depletion of Firmicutes and 
increase of the Proteobacteria phyla, although the exact contribution of this dysbiosis to 
the inflammatory process remains unclear (Matsuoka and Kanai, 2015). So far the only 
clear evidence of bacterial impact on the etiology of inflammation comes from TNFΔARE 
mice, which develop tumor necrosis factor (TNF)-dependent CD. Transplantation of 
dysbiotic microbiota from these mice to their germ-free siblings causes CD-development 
(Schaubeck et al., 2015). There are also several bacteria associated with IBD: Mycobacterium 
avium paratuberculosis (MAP) (Feller et al., 2007), adhesive-invasive E.  coli (AIEC) 
(Barnich and Darfeuille-Michaud, 2007), Fusobacterium varium (Ohkusa et al., 2002) 
and enterotoxigenic Bacteroides fragilis (ETBF) (Prindiville et al., 2000), which invade 
the intestinal epithelial cells.
Immune system. Microbial flora is the main stimulant of the immune system the response 
of which is dysregulated in IBD. During inflammation, many of the activated immune 
cells translocate to the mucosa where they express cytokines, chemokines and integrins. 
CD+ T cells produce increased levels of T helper cell (Th)1/(Th)17-type cytokines in CD, 
while Th2/Th17-type cytokines, produced by CD+ T cells and NK T cells are elevated 
in UC (Xu et al., 2014). Dysregulation of immune system is very often a result of the 
changes in genes linked with immunity, e.g. NOD polymorphism, as described in Table 4. 
Environmental factors. Smoking has been one of the major environmental factors, which 
influences IBD development. Interestingly, smoking seems to protect from UC development 
while it has a deleterious effect on CD, probably due to microbe changes in the intestine 
(Lakatos et al., 2013). Another contributor to IBD development is the type of diet. IBD 
patients have lower levels of vitamin D, which suggests its protective role in IBD development 
(Joseph et al., 2009). This would explain a higher incidence of IBD among Nordic populations 
(Shivananda et al., 1996), which are exposed to less sunlight, a main promotor of vitamin 
D synthesis. Studies also show a promising inhibitory effect of vitamin D on TNF, which 
brings into consideration supplementation of vitamin D in IBD treatment (Zhu et al., 2005; 
Zator et al., 2014). Studies of macronutrients revealed that the most essential nutrient, 
which reduces the risk of IBD development is fiber (Galvez et al., 2005; Ananthakrishnan 
et al., 2013). There are several mechanisms explaining the role of fiber in protection from 
IBD. Fiber is metabolized by intestinal microbiota into SCFAs, which have an inhibitory 
role on the transcription of inflammatory mediators like TNF or IL-1 (Galvez et al., 2005). 
Moreover, fiber supports the maintenance of the intestinal barrier and helps in preventing 
the translocation of E. coli through the colonic epithelium (Roberts et al., 2010).
2.4.1.2. Animal models of IBD
Since IBD is an idiopathic chronic disease, there have been several animal models created 
to study the possible mechanisms behind its development.
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Chemically induced IBD-models. The most commonly used chemical agent, which 
induces murine colitis is dextran sulfate sodium (DSS). DSS is a sulfated polysaccharide 
salt of a molecular weight between 5 – 50 kDa. DSS given in the drinking water to rodents 
causes colitis, which resembles human UC. There are many factors, which influence 
the activity of DSS including: molecular weight (the higher, the more severe colitis is), 
duration (acute: 1-2 weeks vs. chronic: 3-5 1-week cycles with 1-2 weeks rest in between), 
dosage (1-5%), animal sex (higher susceptibility in males) and background (the most 
susceptible are Balb/c and C3H/HeJ strains) (Goyal et al., 2014). The exact mechanism 
of DSS transport through intestinal epithelial cells remains unclear; however, some data 
suggest DSS binding into complexes with medium chain fatty acids (MCFA) and in this 
form passing through the colon cells (Laroui et al., 2012). DSS might also be absorbed 
together with water and electrolyte from the lumen colonized by bacteria (Chassaing 
et al., 2014). DSS has a toxic effect on epithelial cells leading to their erosion and colon 
barrier break (Chassaing et al., 2014), which results in bloody diarrhea, weight loss, or 
eventually death (Goyal et al., 2014). Since the first day of the application, DSS induces 
the upregulation of Th1 inflammatory mediators like IL-1, IL-12, TNF and IFN-γ and 
causes the loss of zonula occludens-1 (ZO-1) in the tight junctions (Poritz et al., 2007; 
Yan et al., 2009). Interestingly, the Th1 pattern is shifted in the chronic DSS-colitis into 
the Th2-type inflammatory response with the increased levels of IL-4, IL-6 and IL-10 
(Alex et al., 2009). There are also histological changes observed in the colonic mucosa 
upon DSS treatment. Acute DSS treatment usually causes mucin depletion and necrosis 
leading to the loss of epithelium, while chronic DSS treatment results in mononuclear 
leukocyte infiltration (Goyal et al., 2014). Other chemically induced models of IBD are 
2,4-dinitrobenzene sulfonic acid (DNBS) and 2,4,6-trinitrobenzene sulfonic acid (TNBS) 
(Goyal et al., 2014). TNBS is more effective at lower concentration than DNBS due to an 
extra reactive nitro group. Both of the compounds are haptens, which by binding to the 
proteins turn into antigens that elicit an immune response. DNBS and TNBS are applied 
rectally dissolved in 45-50% ethanol, which breaks the colonic epithelial barrier and, 
thus, enables haptens to act and induce predominantly CD-resembling inflammation 
(Motavallian-Naeini et al., 2012). The mice subjected to DNBS and TNBS suffer 
from weight loss, bloody diarrhea and prolapse. The increase in Th1-type cytokines, 
prostaglandins and myeloperoxidase (MPO) is observed at the molecular level, while 
transmural necrosis with neutrophil infiltration and edemas are seen at the histological 
level (Goyal et al., 2014). 
Genetically induced IBD-models. IL-10 knock-out (IL-10-/-) mice lack one of the most 
important anti-inflammatory cytokine IL-10 and develop chronic enterocolitis (Kuhn 
et al., 1993). IL-10 is expressed by a broad range of cells of both innate (Th1, Th2 and 
Th17, TReg, CD8+ T and B cells) and adaptive (DC, NK and mast cells, macrophages, 
eosinophils and neutrophils) immunity (Saraiva and O'Garra, 2010). The role of IL-10 is 
to inhibit activated macrophages and dendritic cells, which leads to the resting state of the 
immune system. In case of IL-10  loss, macrophages are constantly active, which results in 
inflammation resembling human CD (Abbas Abdul K., 2010; Goyal et al., 2014). Another 
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example of genetically induced IBD model is the K8-knock-out (K8-/-) mouse which in 
the FVB/N strain develops early chronic colitis resembling human UC (Baribault et 
al., 1994). It has been observed that colitis in K8-/- is amenable to antibiotic treatment 
(Habtezion et al., 2005), suggesting the involvement of bacteria in this phenotype. 
2.4.1.3. The role of epithelial inflammasomes and IL-22 pathway in IBD
Inflammasomes are multiprotein complexes expressed in the colon mainly by 
macrophages and intestinal epithelial cells (IECs). The inflammasome complex consists 
of NOD-like receptor (NLR) sensor molecule, which is bound to pro-caspase via the 
adaptor protein ASC (Guo et al., 2015). NLR senses different types of ligands including 
microbial products (Mariathasan et al., 2006) and ROS (Martinon, 2010), upon which 
inflammasomes assemble. This leads to pro-caspase self-cleavage and release from the 
inflammasome complex. In a canonical inflammasome pathway, activated caspase-1 
cleaves IL-1β and IL-18 to their mature forms. So far, two studies showed the involvement 
of IFs in the regulation of NLRP3 inflammasome activity: keratins in the skin (Roth et 
al., 2012) and vimentin in the lungs (dos Santos et al., 2015). Most of the knowledge 
about inflammasomes in the colon comes from the studies on macrophages. However, 
the inflammasomes have also been detected in the IECs. The role of inflammasomes 
in epithelium is still an object of extensive studies. The NAIP/NLRC4 epithelial 
inflammasomes were found to protect from bacterial colitis models (Nordlander et al., 
2014; Sellin et al., 2014) as well as colitis-induced tumorigenesis (Hu et al., 2010; Allam et 
al., 2015), but the underlying mechanisms of these observations are missing. Studies with 
Nlrp6-/- mice also showed increased susceptibility to DSS-colitis and AOM/DSS-induced 
CRC (Chen et al., 2011; Elinav et al., 2011). At the molecular level, NLRP6 was shown 
to influence mucus production by regulating the autophagy of goblet cells (Wlodarska 
et al., 2014). The most controversial role among epithelial inflammasomes has NLRP3, 
since animal studies present its both protective and contributory role to colitis and CRC 
development (Allen et al., 2010; Huber et al., 2012). In the study, (Huber et al., 2012) 
also showed active inflammasome-IL-18 to decrease the expression of interleukin-22 
binding protein IL-22BP, an inhibitor of IL-22 activity (Fig. 9B). As mentioned earlier 
(see Table 4), NLRP3 polymorphism may predispose humans to Crohn’s disease (Villani 
et al., 2009).
IL-22 is a Th17-type cytokine produced by various immune cells, mainly activated T cells, 
natural killer (NK) cells and natural killer T (NKT) cells (Witte et al., 2010). The role 
of IL-22 is to stimulate proliferation, production of antimicrobial peptides and tissue 
protecting proteins in epithelial cells by activation of signal transducer and activator 
of transcription 3 (STAT3). This transcription factor is activated during the JAK/STAT 
pathway, which IL-22 induces by binding to IL-22RA1/IL-10R2 receptors placed on the 
epithelial cell membrane (Fig. 9A) (Bleicher et al., 2008). Increased levels of IL-22 are 
often present in psoriasis and IBD patients (Sonnenberg et al., 2011). Interestingly, IL-22 
activation through P-STAT3 can stimulate both wound healing and tumorigenesis in the 
colon (Pickert et al., 2009; Jiang et al., 2013). As mentioned earlier, the loss of IL-22BP in 
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the colon, leads to prolonged activity of IL-22 and increased tumorigenesis (Huber et al., 
2012). However, apart from the NLRP3 inflammasome (Huber et al., 2012) and retinoic 
acid (Martin et al., 2014), (Fig. 9B), the regulators of IL-22BP are unknown. 
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Figure 9. The IL-22 pathway and the IL-22BP regulation by active NLRP3 inflammasome 
in the colon. A. IL-22 is produced by immune cells in lamina propria of the colon. IL-22 in 
its active state binds IL-22RA1 and IL-10R2 receptors expressed at the membrane of epithelial 
cells. This binding leads to the activation of JAK/STAT pathway, upon which STAT3 is 
phosphorylated, dimerizes and translocates to the nucleus to serve as a transcriptional factor 
for genes involved in antimicrobial peptide production, tissue protection and epithelial cell 
proliferation. IL-22 remains inactive when bound to IL-22BP, which is produced by dendritic cells. 
B. The regulation of IL-22BP levels is barely known. The current studies suggest that active 
inflammasome/IL-18 pathway decreases the levels of IL-22BP, while retinoic acid increases it. 
Based on (Huber et al., 2012; Martin et al., 2014; Sabat et al., 2014).
2.4.1.4. IBD treatment
As mentioned earlier, IBD is a complex disease including different origin, severity 
and site of action; thus, there are various IBD therapies available: medical, biological, 
nutritional and surgical. In medical therapy drugs from numerous classes are used: 
aminosalicylates, antibiotics, corticosteroids and immunomodulators (The Crohn's 
& Colitis Foundation of America). Aminosalicylates contain 5-aminosalicylic acid 
(5-ASA) as an active compound, which inhibits the transcription factor PPARγ 
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(Rousseaux et al., 2005). Antibiotics aim to manipulate the microbiome by removing 
certain bacteria, which may contribute to IBD pathology and, thus, reduce the immune 
response. Corticosteroids have both anti-inflammatory and immunosuppressive 
effects, however, due to the side effects they are recommended to be used in low doses 
for short periods of time. Immunomodulators modulate the response of the immune 
system and very often are used with corticosteroid to increase their efficiency (The 
Crohn's & Colitis Foundation of America). Biological therapy is based on monoclonal 
antibodies targeted against TNF-α, α4 and α4β7 integrins and interleukins, e.g. IL-
12/23 (Moss, 2015). Moreover, there are attempts to cure IBD with fecal microbiota 
transplantation (FMT). The aim is to let bacteria from the healthy donor colonize 
the gut of the IBD patient, which might overpopulate the harmful microbiota. So far 
the efficacy of this method varies depending on the case (Colman and Rubin, 2014). 
Nutrition therapies are often a must in IBD due to the malnutrition and, thus, increased 
risk for osteoporosis and anemia development. IBD patients are mostly supplemented 
with vitamin D, calcium and iron (Hwang et al., 2012). Some studies also suggest a 
diet reduced in gluten, high fat, emulsifiers and maltodextrin (Sarbagili-Shabat et al., 
2015). Surgery is the last option for UC when other methods fail. The most common 
surgery performed is total proctocolectomy, in which colon and rectum are removed. 
Proctocolectomy is often assisted with ileoanal pouch anastomosis – the intestinal tract 
reconnection using small intestine. In case of CD, surgery is a temporary solution, 
since CD reemission rate is high in this disease and the small intestine cannot be totally 
removed. This surgery is also a combination of resection and anastomosis (The Crohn's 
& Colitis Foundation of America). 
2.4.2. Colorectal Cancer (CRC)
2.4.2.1. Epidemiology and mortality of CRC
Colorectal cancer (CRC) is the third most commonly developed type of cancer worldwide 
(Jemal et al., 2011). The highest CRC incidence is observed in developed countries and 
its increase seems to follow the economic growth. So far the highest CRC incidence rates 
are in Australia and New Zealand, in which CRC development is 10-fold higher than in 
African countries with the lowest CRC incidence worldwide (Ferlay J, 2013).
CRC is the fourth most deadly cancer type worldwide. The highest mortality rates are 
in Central and Eastern Europe – 20.3 per 100,000 cases for men, 11.7 per 100,000 for 
women and the lowest in Western Africa – 3.5 and 3.0 per 100,000 cases, for men and 
women respectively (Ferlay J, 2013). The prediction of mortality rates in the USA is 37%, 
estimated as 49,700 deaths out of 132,700 new CRC cases in 2015 (American Cancer 
Society).
2.4.2.2. Risk factors and screening for CRC
Age is the most crucial factor for CRC development - 90% of the people suffering from 
CRC are at age 50 and older. This is due to the accumulation of mutations during lifespan. 
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A big role in CRC development is played by genetics. The chance of developing CRC 
increases 80% when having a first-degree relative suffering from this disease. To the most 
common hereditary cases of CRC belong familial adenomatous polyposis (FAP) and 
hereditary nonpolyposis colon cancer (HNPCC; Lynch Syndrome). Lifestyle is also known 
to contribute to the development of CRC remarkably. Diet rich in red and processed 
meat increases CRC incidence probably due to the high content of iron, which stimulates 
cell growth. Alcohol consumption and smoking promote carcinogenesis of colon and 
rectum. Obesity also has a strong contribution to the CRC incidence. According to some 
studies, obese people can have even a 33% higher risk of developing CRC compared to 
healthy non-obese individuals (Ma et al., 2013). 
There are different methods available to screen for CRC. The most reliable so far is 
colonoscopy (Lieberman et al., 2000), although its invasiveness can cause perforation 
and bleeding of the colon and is less effective in detecting changes in the proximal colon 
(Imperiale et al., 2000). A less invasive alternative for colonoscopy is sigmoidoscopy; 
however, it screens only the most distal part of the colon. There are also several stool 
tests available on the market, which detect blood in the feces: fecal occult blood test 
(FOBT), fecal immunochemical test (FIT) and Cologuard test. FOBT detects hem using 
a chemical called guaiac with an effectiveness varying between 50-79%, while FIT applies 
an antibody recognizing hemoglobin and shows an effectiveness at 55-100% (Willyard, 
2015). Cologuard also screens for KRAS gene mutations and gene modifications 
from colon epithelial cells present in the stool and its effectiveness was valued as 92% 
(Imperiale et al., 2014). Although the effectiveness rates of stool tests is relatively high, 
the colonoscopy examination is still recommended to confirm their results. 
2.4.2.3. Molecular pathways leading to CRC
There are three major molecular pathways leading to CRC development: chromosomal 
instability (CIN), microsatellite instability (MSI) and CpG island methylation phenotype 
(CIMP) (Bogaert and Prenen, 2014). CRC is believed to arise from a sequence of 
mutations. In 1990, Fearon and Vogelstein presented the model of adenoma-carcinoma 
sequence followed by CIN (Fig. 10). Nevertheless, tumors can also arise from another 
pathway called serrated pathway like many tumors of MSI and CIMP-origin (Fig. 11).
Chromosomal instability (CIN). CIN is a cause of 70% CRC cases and is defined as an 
accumulation of numerical and structural abnormalities in the chromosomes (Bogaert 
and Prenen, 2014). Among mechanisms causing CIN are defects in chromosome 
segregation, centromere and telomere dysfunction and deficiency of the DNA damage 
response. The consequences of CIN are usually loss of heterozygosity (LOH), aneuploidy 
and subchromosomal genomic amplifications (Hung, 2013). CIN very often affects genes 
from the Wnt pathway (genes encoding for Apc and β-catenin proteins), Ras pathways 
and TP53 (Table 5).
Mutations in the APC tumor suppressor gene are the most common in CRC and mainly 
lead to protein truncation. As mentioned earlier (see section 2.2.1), Apc is involved in the 
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Wnt-pathway and forms a complex with β-catenin. Truncated Apc disrupts the complex 
formation causing β-catenin accumulation in the cytoplasm and translocation to the 
nucleus, where it activates genes of tumor growth and invasion (Hung, 2013). Recent data 
show that Apc restoration leads to homeostasis in the colon even in the presence of other 
CRC-inducing mutations, a phenomenon which highlights the importance of Apc in 
tumorigenesis (Dow et al., 2015). The β-catenin oncogene CTNNB1 can be mutated itself, 
an event observed in 50% of tumors without APC mutations. KRAS is another oncogene 
often mutated in CRC. Single nucleotide point mutations in this gene lock the protein in 
its active state with bound guanosine triphosphate (GTP), which activates Ras pathway 
and thus affects multiple cellular functions like differentiation and proliferation. One of 
the Ras effector proteins is phosphatidylinositol 3-kinase (PIK3, encoded by PIK3CA), of 
which mutant forms also are found in the CRC. Nearly half of colorectal tumors have a 
mutation in the TP53 gene encoding for p53- tumor suppressor, which as a transcription 
factor regulates cellular responses to stress. Loss of DCC, SMAD2 and SMAD4 alleles at 
18q chromosome has also been reported to lead to increased tumorigenesis in the colon 
(Pino and Chung, 2010). 
Table 5. Colorectal cancer mutations arising from the chromosomal instability pathway. 
Gene Chromosomal 
location
Prevalence of 
mutations (in %)
Function of gene product
Tumor suppressor genes
APC 5q21 30-70 Wnt signaling inhibition
TP53 17p13 40-50 Cell cycle arrest, apoptosis 
induction
SMAD2, SMAD4 18q21 10-20 Intracellular mediators of the 
TGF-β pathway
DCC 18q21 6 Cell surface receptor for netrin-1
Oncogenes
KRAS 12p12 30-50 Cell proliferation, survival, and 
transformation
CTNNB1 3p22 4-15 (50*) Regulation of Wnt pathway target 
genes promoting tumor growth 
and invasion
PIK3CA 3q26 20 Cell proliferation and survival
*Identified in 50% tumors without APC mutations. Copied from (Pino and Chung, 2010).
Microsatellite instability (MSI). Nearly 15% of CRC cases arise from microsatellite 
instability (MSI), from which 12% are identified as sporadic cases and 3% as heritable 
cases of Lynch syndrome (Boland and Goel, 2010; Hung, 2013). Microsatellites are 
repeatable 1-6 base pair long nucleotide sequences spread through the genome. They are 
prone to accumulate mutations because DNA polymerase cannot bind them efficiently, 
which results in nucleotide insertions and deletions. Mutations in microsatellites are 
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usually repaired by DNA mismatch repair (MMR) system including its main enzymes: 
MLH1 and MSH2. Silencing of the gene encoding for MLH1 leads to a dysfunctional 
MMR system and hypermutability in microsatellites. Methylation of MLH1 promoter 
is an epigenetic mechanism behind MLH1 silencing in sporadic CRC (Bogaert and 
Prenen, 2014) and is also present in CIMP. MSI is also associated with diploidy, frequent 
mutation in BRAF and originates from the serrated pathway in sporadic CRC (Hung, 
2013). The best characterized mutation caused by MSI is a mutation in transforming 
growth factor β type 2 receptor (TGF-βR2) gene. Loss of TGF-βR2 leads to uncontrolled 
growth of colonic epithelial cells and tumor growth due to the lack of response to TGF-β 
(Markowitz et al., 1995). The other genes affected by MSI are e.g. Axin-2, MLH3, BAX; 
however, the functional significance of their silencing in CRC remains unclear (Hung, 
2013). 
CpG Island Methylation Phenotype (CIMP). Another 15% of CRC cases present a CpG 
Island Methylation Phenotype (CIMP) (Worthley and Leggett, 2010). CpG islands 
are DNA regions rich in dinucleotide cytosine (C) and guanine (G) sequences. They 
are usually present in the 5’ promotor region and are a favorite substrate for DNA 
methyltransferases (DNMT), which add a methyl group to cytosine. Methylation of 
cytosine leads to gene silencing. This way some tumor suppressor genes are inactivated 
in CRC, e.g. CDKN2A encoding for p16 protein, an inhibitor of Cdk4 and Cdk6 in the 
cell cycle (Nazemalhosseini Mojarad et al., 2013). 
Adenoma-carcinoma sequence. As mentioned at the beginning of the paragraph 2.4.2.3, 
CIN tumors arise from an adenoma-carcinoma sequence (Fig. 10), in which inactivating 
mutations in tumor suppressor genes and activating mutations in oncogenes appear. 
According to Fearon’s and Vogelstein’s model, mutation in Apc/β-catenin is the first 
event leading to a transformation of normal epithelium into a dysplastic aberrant crypt 
foci (ACF). Next, mutations in KRAS cause ACF growth into adenoma, which turn into 
adenocarcinoma when mutations in TP53, PIK3CA or loss of genes at chromosome 18q 
occur (Fearon and Vogelstein, 1990; Hung, 2013).
normal 
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APC*/β-catenin* KRAS*
TP53*, PIK3CA*,
18q loss
CIN
Figure 10. The adenoma-carcinoma sequence in the colon mucosa. This sequence arises from 
an increase in chromosomal instability (CIN). The first step of CRC is a formation of dysplastic 
aberrant crypt foci (ACF) caused by mutations in APC and/or β-catenin. ACF turn into adenomas 
upon KRAS mutations and next into adenocarcinoma upon mutations in TP53 and PIK3CA and 
18q loss. Adapted from (Hung, 2013).
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Serrated pathway. Nearly 30% of CRC are developed via the serrated pathway, which is 
followed by many tumors of CIMP- origin (Fig. 11) (Bettington et al., 2013). The name 
of this pathway originates from a serrated looking like epithelium formed at low levels 
of apoptosis. Decreased levels of apoptosis result from activated MAPK-ERK pathway. 
Based on the mechanism activating MAPK-ERK pathway, there are two kinds of pathways 
leading to serrated adenocarcinoma: traditional and sessile serrated pathway. Traditional 
serrated pathway originates from KRAS mutation that activates MAPK-ERK pathway 
and is more common in the distal colon. 
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Figure 11. The sessile and traditional serrated pathway in the colon mucosa. This sequence arises 
from a high (sessile pathway) or low (traditional pathway) increase in CpG Island Methylation 
Phenotype (CIMP). The first step is an activation of MAPK-ERK pathway by KRAS (traditional 
pathway) or BRAF mutation (serrated pathway) which leads to the formation of hyperplastic 
aberrant crypt focus (ACF). The final methylation of MGMT or MLH1 in traditional and sessile 
pathway, respectively, cause a development of serrated adenocarcinoma. Adapted from (Patai et 
al., 2013).
Sessile serrated pathway originates from a BRAF mutation that activates the MAPK-ERK 
pathway and is more common in the proximal colon. This pathway gives rise to serrated 
hyperplastic ACF, which turn into polyps when the expression of two tumor suppressor 
genes: p16 and IGFBP7 is increased. When these genes become methylated, polyps grow 
into sessile serrated adenomas – the adenomas that grow directly from the colon wall 
without any stem. Serrated adenocarcinoma arises from sessile adenoma when MLH1 is 
methylated. In this pathway CIMP profiles are usually high (Bettington et al., 2013; Patai 
et al., 2013).
2.4.2.4. IBD as a risk factor for developing CRC
IBD is a well-known risk factor for developing CRC. Colitis-associated CRC incidences 
constitute 1% of all CRC cases and is low due to colonoscopic surveillance, colectomy 
and chemopreventive effects of 5-ASA (Beaugerie and Itzkowitz, 2015). The risk of 
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CRC development increases with the duration of IBD. The other factors that influence 
CRC development in IBD patients are: area affected by colitis, severity of inflammation, 
heritable genetic factors and presence of primary sclerosing cholangitis (Feagins et al., 
2009). Inflammation is also caused by oxidative DNA damage, which promotes the 
mutations. The molecular pathogenesis of colitis-associated cancer is similar to sporadic 
cases of CRC. However, the same mutations occur in different timing and frequency 
in the dysplasia-carcinoma sequence (Fig. 12). TP53 mutations usually initiate the 
transformation of normal mucosa into dysplasia, while mutations in APC cause the 
dysplastic tissue to transform into adenocarcinomas. Dysplastic lesions that arise in IBD-
associated CRC are usually flat and of less distinct borders. 
normal 
mucosa
indefinite
dysplasia
low-grade
dysplasia
adenocarcinoma
APC*KRAS*TP53*
high-grade
dysplasia
Figure 12. The IBD-CRC associated pathway. TP53 mutations occur early and lead to the 
transformation of normal epithelium to the dysplastic one. The grade of dysplasia is increasing 
with KRAS mutations. APC mutations occur at the late stage of CRC formation. Adapted from 
(Beaugerie and Itzkowitz, 2015).
Interestingly, studies on IBD-animal models reveal that mice do not develop cancer under 
germ-free conditions or upon antibiotic treatment, which highlights the importance of 
microflora contribution to the CRC phenotype (Itzkowitz and Yio, 2004; Beaugerie and 
Itzkowitz, 2015). 
2.4.2.5. Mouse models of CRC
Mouse models of CRC are useful to study the mechanism of pathogenesis and validate 
new therapeutic agents. 
Chemically induced CRC-models. Mice very rarely develop spontaneous CRC. 
Thus, several different carcinogens are used for the CRC studies, for example: 
dimethylhydrazine (DMH) and its metabolite azoxymethane (AOM) often in a 
combination with inflammatory agent DSS, 2-amino-1-methyl-6-phenyl-imidazol [4,5-
b] pyridine (PhIP), N-methyl-N’-nitro-N-nitrosoguanidine (MNNG), 3,2’-dimethyl-
4-aminobiphenyl (DMBA) and 3,2’-dimethyl-4-aminobiphenyl (DMBGA). The most 
commonly used agent inducing CRC is AOM due to its high stability and potency 
(Neufert et al., 2007). AOM, in order to react with DNA, needs to be activated by several 
enzymatic reactions (Fig. 13A), which start in the liver. A final metabolic product of 
AOM, methyl cation reacts with DNA in the colon and adds a methyl group at the O6 
and N7 position of the guanine. Formation of O6-methyl-deoxyguanosine is mutagenic 
(Fig. 13B). This molecule acquires different hydrogen bonding properties and instead 
of binding cytosine it binds thymidine. The thymidine binding causes a substitution of 
guanine into adenine during the DNA replication, which results in mutations (Brown 
40 Review of the Literature 
and Brown; Rosenberg et al., 2009). The mutations caused by AOM are usually in KRAS, 
β-catenin and TGFβ genes (Chen 2009). The number of tumors induced in the AOM 
model is dose, duration and strain dependent, e.g. in FVB/N strain the average tumor 
number per mouse is 3.6 upon 10 mg/kg AOM dose once per week for 4 weeks and 
sacrifice after 20 weeks (Nambiar et al., 2003).
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Figure 13. The AOM metabolic pathway. A. Dimethylhydrazine (DMH) is a precursor of 
azoxymethane (AOM), which undergoes metabolic activation by hepatic enzyme cytochrome 
P450 2E1 (CYP2E1) into methylazoxymethanol (MAM). Next, MAM is metabolized into methyl 
diazonium ion, which gives rise to methyl cation in the colon. B. Methyl cation reacts with DNA 
in the colon and leads to the methylation of 2’-deoxyguanosine into mutagenic O6-methyl-
deoxyguanosine and non-mutagenic N7-methyl-deoxyguanosine. -dR deoxyribose. Adapted from 
(Brown and Brown; Rosenberg et al., 2009).
Genetically induced CRC-models. There are numerous genetically engineered mouse 
models of CRC available. The most popular is a model for FAP, the ApcMin/+ mice, which 
carry a germline mutation in APC leading to multiple intestinal neoplasia (Min). This 
model, however, develops adenomas mostly in small intestine, while in humans with 
FAP they are localized in colon. The ApcMin/+ adenomas usually do not progress into 
adenocarcinomas due to a short lifespan of the animals. However, a new model of 
ApcMin/+ mice - FabplCre, Apc15lox/+ has been created, which has a longer lifespan and 
develops adenocarcinomas in the colon (Robanus-Maandag et al., 2010). Adenoma 
multiplicity in ApcMin/+ is dependent on the mouse strain and environmental factors 
including type of bacteria or diet (Karim and Huso, 2013). Moreover, the number of 
tumors in different ApcMin/+ strains are affected by the modifiers of Min called Mom. 
Apart from ApcMin/+ models, conditional knock-out mouse models of MSH2 and MLH1 
develop lymphomas in the intestinal tract, which mimic HNPCC (Kucherlapati et al., 
2010; Reiss et al., 2010).
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2.4.2.6. CRC treatment
Surgery is used at an early stage of CRC and is successful in 90% of the cases. Metastatic 
CRC (mCRC) is usually treated with chemotherapy combined with molecular therapy. 
This combination is used due to tumor heterogeneity and ability to compensate for loss by 
generating mutations in other pathways. There are several drugs available in the market 
for mCRC treatment (Table 6) (Sridharan et al., 2014; Scudellari, 2015). The oldest CRC 
drug available is 5-fluorouracil, a DNA synthesis inhibitor used in chemotherapy. The 
newer chemotherapeutics used in a combination with 5-fluorouracil are capecitabine, 
irinotecan, and oxaliplatin. The first medicine of a targeted therapy was bevacizumab, 
a monoclonal antibody, which by binding to vascular endothelial growth factor A 
(VEGF-A) blocks the vasculogenesis. The other drug from this class is aflibercept, which 
not only blocks VEGF but also platelet-derived growth factor (PDGF). Among drugs 
against mCRC are also epidermal growth factor receptor (EGFR) antibodies: cetuximab 
and panitumumab. EGFR is a receptor tyrosine kinase, the phosphorylation of which 
leads to the activation of pathways like MAPK, Akt and JNK resulting in DNA synthesis 
and proliferation. The disadvantage of EGFR antibodies is their inefficiency if KRAS, a 
protein downstream from EGFR, is mutated. The newest mCRC drug in the market is 
regorafenib, which inhibits many kinases (Sridharan et al., 2014). A big problem in the 
field is the use of more than two drugs for mCRC due to high toxicity in the patients. 
In order to solve this problem scientists and clinicians try to find biological markers: 
characteristic genetic mutations or specific patterns of gene expression. So far, three 
negative biological markers have been found: KRAS, NRAS and BRAF genes, which show 
resistance to cetuximab and panitumumab therapies. In order to find more markers 
and establish precise molecular profiles of the tumors, the next generation sequencing 
and bank of organoids are used. The other issue that needs an urgent solution is finding 
drugs for the most common CRC mutations in RAS genes and Wnt pathway. Attempts to 
develop immunotherapy against CRC have been unsuccessful so far (Scudellari, 2015). 
Table 6. FDA approved agents for metastatic CRC treatment.
Class Agent Characteristics
Cytotoxic 
chemotherapy 5-fluorouracil
Fluoropyrimidine,  
DNA synthesis inhibitor
Capecitabine Fluoropyrimidine,  DNA synthesis inhibitor
Irinotecan Topoisomerase I inhibitor, DNA synthesis inhibitor
Oxaliplatin Platinum-based compound, DNA synthesis inhibitor
VEGF inhibitor Bevacizumab Humanized monoclonal antibody, binds VEGF-A
Aflibercept
Recombinant fusion molecule, contains extracellular 
domain of VEGFR-1 and -2 fused to IgG-1 Fc part, binds  
VEGF-A,VEGF-B, PGF-1 and PGF-2
EGFR antibody Cetuximab Chimeric IgG1 antibody, binds EGFR
Panitumumab Human igG2 antibody, binds EGFR
Kinase inhibitor Regorafenib Binds RTK, inhibits VEGF and EGFR
Based on (Sridharan et al., 2014; Scudellari, 2015)
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OUTLINE AND AIMS OF THE THESIS
Although K8 is the main IF expressed in the colon, its exact role remains ambiguous. 
The general aim of this thesis was to investigate the role of K8 in colon cell fate, colitis-
induced carcinogenesis and metabolism. Most studies were performed using K8-/- mouse 
model, which spontaneously develops early chronic colitis resembling human IBD. 
The specific aims of the thesis were:
Aim 1: Study the effect of keratins on proliferation and differentiation (Study I.).
Aim 2: Analyze if K8-/- mice are susceptible to developing colon cancer basally and in 
genetic or carcinogen colorectal cancer models. Find mechanism for increased 
tumorigenesis (Study II.).
Aim 3: Determine whether keratins are involved in the regulation of colon energy 
metabolism (Study III.).
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EXPERIMENTAL PROCEDURES
Detailed information on experimental procedures used in the thesis are described in the 
manuscripts (I.-II.) and original publication (III.). 
Animals
Name (background) Study
ApcMin/+ (FVB/n) II.
BALB/c III.
K8+/+, K8+/-, K8-/- (FVB/n) I.-III.
K8+/+ApcMin/+, K8+/-ApcMin/+, K8-/-ApcMin/+ (FVB/n) II.
Cell lines
Name Study
Caco-2, human colorectal adenocarcinoma III.
HEK293, HEK293-FLN, human embryonic kidney cells, expressing full length Notch (FLN) I.
HT-29, human colorectal adenocarcinoma III.
MEFvim-/-, mouse embryonic fibroblasts from vimentin knock-out mice I.
Antibodies
Target, name (manufacturer) Application Study
Alexa Fluor 488 (ThermoFisher Scientific) staining I., III.
Alexa Fluor 546 (ThermoFisher Scientific) staining I., III.
Cytochrome c (Cell signaling) WB III.
FLN, c-20 (Santa Cruz Biotechnology) WB, staining I.
GFP (Clontech) WB III.
H3 (Abcam) WB I.
HMGCS2 (AVIVA and Geneway) WB, staining III.
Hsc70 (Enzo Life Sciences) WB I.-III.
IL-18 (R&D) WB II.
IL-22BP (R&D) WB II.
K8, Troma I (Developmental Hybridoma Bank, University of Iowa) WB, staining I.-III.
K8, 273 (kind gift of John Eriksson’s laboratory) IP I.-II.
K8/K18, 275 (kind gift of John Eriksson’s laboratory) IP I.-II.
MCT1 (Chemicon and Santa Cruz Biotechnology) WB, staining III.
Caspase-1 (AdipoGen) WB II.
PHH3 (Cell signaling) WB, staining I.
PPARα (Santa Cruz Biotechnology) WB III.
P-STAT3 (Cell Signaling Technology) WB II.
Prohibitin (Abcam) WB III.
Synaptophysin (Abcam) WB I.
STAT3 (Cell Signaling Technology) WB II.
Tubulin (Sigma-Aldrich) WB III.
WB = western blotting, IP = immunoprecipitation 
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Methods 
Name Study
2D DIGE III.
Antibiotic treatment I.-III.
AOM- and AOM/DSS- induced colorectal carcinogenesis II.
BrdU staining I.
Cell culture I., III.
Colon permeability assay, FD4 II.
DSS-induced colitis II.-III.
Image analysis I.-III.
Immunofluorescence I., III.
Immunohistochemistry I.
Immunoprecipitation (IP) I.-II.
Mitochondria isolation and HMGCS2 enzyme activity assay III.
PCR as a method for mouse genotypying I.-III.
Periodic acid-schiff (PAS) staining I.
Quantitative reverse transcription PCR I.-III.
SDS-PAGE and immunoblotting I.-III.
Statistical analysis I.-III.
Transmission electron microscopy III.
Selected reagents
Name (manufacturer) Application Study
5-Bromo-2’-deoxyuridine, BrdU  
(BD Biosciences)
BrdU staining I.
Azoxymethane, AOM  
(Sigma-Aldrich)
Colorectal carcinogenesis II.
Cycloheximide, CHX (Sigma-Aldrich) Inhibition of translation I.
DAPI (Life Technologies) Immunofluorescence I., III.
Dextran sulphate sodium, DSS (TdB) Colitis induction II.-III.
Fluorescein isothiocyanate–dextran, FD4 (TdB) Colon permeability assay II.
Imipenem (Hospira) Antibiotic treatment I.-II.
Lipofectamine 2000 (Invitrogen) Transfection III.
MG132 (Santa Cruz) Inhibition of proteasome I.
Myers hemalum (Merck) PAS staining I.
Periodic acid (Sigma-Aldrich) PAS staining I.
Protein G sepharose (GE Healthcare) Immunoprecipitation I.-II.
Shiff reagent (Merck) PAS staining I.
Vancomycin (Hospira) Antibiotic treatment I.-II.
siRNA
Name (Manufacturer) Study
KRT8 Pre-design Chimera RNAi (Abnova) III.
KRT18 Pre-design Chimera RNAi (Abnova) III.
Naito1 scrambled negative control Pre-design Chimera RNAi (Abnova) III.
KRT8 siMAX siRNA (Eurofins Genomics) III.
Nontarget scrambled negative control siMAX siRNA (Eurofins Genomics) III.
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Plasmids
Name (Manufacturer) Study
FLN (kind gift of Cecilia Sahlgren’s and Urban Lendahl’s laboratory) I.
K18 (kind gift of Bishr Omary’s laboratory) I.
K19 (kind gift of Bishr Omary’s laboratory) I.
K8 (kind gift of Bishr Omary’s laboratory) I.
K8 S74A (kind gift of Bishr Omary’s laboratory) I.
MCT1-GFP (kind gift of Pradeep Dudeja’s laboratory) III.
NICD-GFP-Flag (kind gift of Cecilia Sahlgren’s and Urban Lendahl’s laboratory) I.
PCDNA3.1(AddGene) I.
ΔE Notch1 (kind gift of Cecilia Sahlgren’s and Urban Lendahl’s laboratory) I.
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RESULTS AND DISCUSSION
1. K8 regulates differentiation in the colon through Notch1 signaling 
(Study I.)
K8 deletion in mice leads to a broad colonic phenotype including colonocyte 
hyperproliferation (Baribault et al., 1994). The colon epithelium of K8+/- mice express 50% 
less keratins compared to K8+/+ and display increased proliferation (Asghar et al., 2015). 
These data suggest the involvement of keratins in colon epithelial proliferation. Colon 
epithelial tissue originates from stem cells, which differentiate into various cell types. 
As mentioned in section 2.2.2, the master regulator of proliferation and differentiation in 
the colon epithelium is the Notch1 signaling, the regulators of which are largely unknown. 
The aim was to study whether any link exists between keratins and Notch1 in the colon 
and to characterize the population of epithelial cells in the K8-/- colon. 
1.1. K8 binds and colocalizes with Notch 1 in vitro and in vivo
Keratins are known to serve as scaffolds for many proteins (Pan et al., 2013). To find out 
whether keratins are the binding partners of Notch1, a K8/K18 immunoprecipitation 
on K8+/+ colonic epithelium was performed. Subsequent Western blot analysis showed 
that NICD is pulled down together with K8/K18 from both proximal (PC) and distal 
colon (DC) epithelium (I.: Fig. 1A, SFig. 1). To confirm this result and specify which 
part of Notch1 binds to K8/K18, a Notch1 immunoprecipitation was done in mouse 
embryonic fibroblasts lacking vimentin and other IF (MEFvim-/-) and overexpressing 
FLN, ΔE Notch1 or NICD with and without the presence of K8/K18 or K8 S74A/K18. 
Based on the Western blot results, we observed that K8 is co-immunoprecipitated 
with all Notch forms, while K18 was not detected in this complex (I.: Fig. 1B, SFig. 
2A). K8 S74A was also pulled down with NICD from K8 S74A/K18 transfected cells 
as detected by Western blot (I.: Fig 1B) indicating that K8 binding to Notch1 is not 
phosphorylation dependent. Immunostaining of K8 and Notch1 in K8+/+ mouse colon 
and human embryonic kidney cells stably overexpressing FLN (HEK293-FLN) showed 
that K8 colocalize with Notch1 at the plasma membrane and cytoplasm both in vivo 
and in vitro, which was confirmed by image analysis using Manders’ co-localization. 
The coefficients for in vivo were: 0.65 for Notch1 and 0.69 for K8 in the epithelium (p 
= 1) and for in vitro: 0.68 for Notch1 and 0.75 for K8 in the HEK293-FLN cells (p = 1), 
(I.: Fig. 1C-D).
Taken together, our results indicate that K8 and Notch1 bind and colocalize both in vivo 
and in vitro. (I.: Fig. 1C, SFig. 1 and SFig. 2A). The colocalization of Notch1 and K8 at 
the plasma membrane and cytoplasm indicates them as sites of potential protein-protein 
interaction. A similar colocalization between K8 and Notch2 is seen at the plasma 
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membrane in the uretic bud of E17.5 murine kidney (Liu et al., 2013). Interestingly, 
the impairment of Notch2 signaling is also observed in the biliary epithelial cells of 
K19-/- mice treated with the 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) further 
supports the keratin - Notch interactions (Chen et al., 2015).
1.2. Notch1 levels and activity are modified by K8/K18 in in vitro 
cell culture models
Since K8 and Notch1 can bind together, it was tested whether keratins can regulate 
the Notch signaling pathway. First, MEFvim-/- cells were transfected with K8/K18 and 
NICD levels were evaluated. The NICD levels were increased 2-3 fold upon K8/K18 
overexpression (I.: Fig. 2A). Also, overexpression of K8 phosphorylation-deficient 
mutant – K8 S74A resulted in the increase of NICD levels (I.: Fig. 2A). The increase in 
NICD expression was in a keratin-dose dependent manner (I.: Fig. 2B). Furthermore, 
the overexpression of K8/K19 dimer led to the increase in NICD levels (I.: Fig. 2C) 
indicating that the NICD induction is not dependent on the K8 dimeric partner. 
To  investigate whether K8/K18 stabilize Notch1, cycloheximide (CHX) was used to 
block the translation of proteins in MEFvim-/- cells overexpressing NICD alone or 
together with K8/K18 or K8 S74A/K18. The K8/K18-induced NICD levels decreased 
gradually with a similar turnover as that of NICD alone, although the actual levels 
of NICD were 2-3 fold higher in the presence of K8/K18 or K8 S74A/K18 filaments 
(I.: Fig. 2D-E, SFig. 2B). Blocking the proteasome with MG132 for 12h in MEFvim-/- 
cells led to a significant increase in NICD levels only in the absence of keratins (I: Fig. 2F, 
SFig. 2C) compared to the slight increase observed when NICD was co-expressed with 
K8/K18 or K8 S74A/K18 (I.: Fig. 2F). The influence of keratins on the activity of Notch1 
signaling was analyzed by evaluating the mRNA levels of the Notch target gene Hey1. 
The mRNA levels of Hey1 were significantly increased when NICD was overexpressed 
together with K8/K18 compared to NICD overexpression alone, while K8S74A/K18 
overexpression did not have an influence on Hey1 mRNA levels compared to control 
MEFvim-/- cells (I: Fig. 2G). HEK293 and HEK293-FLN cell lysates were also analyzed 
for keratin expression. The Western blot clearly showed that stable FLN overexpression 
led to significant increase in K8 and K18 protein levels compared to control HEK293 
cells (I.: Fig. 2H), further demonstrating a reciprocal regulatory relationship between 
K8 and Notch1. 
Altogether, these data show that stable overexpression of FLN can increase the expression 
of both K8 and K18. This observation is in line with a previous study (Hamidi et al., 
2011) where KRT18 has been found as a target of CSL- a Notch transcriptional factor, 
which is activated by NICD during hematopoiesis. We also show that K8 is able to 
increase the expression of NICD in a dose-dependent manner. This indicates that K8 – 
Notch1 interaction is reciprocal. Moreover, the data with MG132 proteasome inhibitor 
shows that K8/K18 protect Notch1 from proteasomal degradation. Mutation in K8 at 
S74 seems not to have a negative effect on the increase of NICD and its degradation stays 
at the same level regardless of Alanine substitution. Moreover, the overexpression of K8 
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S74A site with NICD does not increase the mRNA levels of Hey1, which suggests that 
K8 S74 phosphorylation may have a regulatory role in Notch signaling activity (I.: Fig. 
2G). How keratins exactly affect Notch1 activity needs further studies. Since keratins 
are known to target proteins at the cell membranes (Toivola et al., 2004; Vijayaraj et 
al., 2009), it can be speculated that keratins facilitate Notch1 receptor cleavage – a 
membrane-proximal site event. Moreover, keratins may prolong NICD activity by 
stabilizing and retaining its pool in the cytoplasm. This might be accomplished 
through 14-3-3 protein - a binding partner of K8/K18 (Liao and Omary, 1996; Ku et al., 
2002b), as recent studies have shown that it facilitates the Notch4 nuclear translocation 
(Ramakrishnan et al., 2015).
1.3. Decreased Notch1 in the K8-/- mouse colon results in a cell 
differentiation shift
The levels and activation of Notch signaling were also analyzed in vivo in the K8-/- colon 
epithelium. Both FLN and NICD were significantly decreased in the K8-/- colon on 
protein level (I.: Fig. 3A-C), while mRNA Notch1 levels remained unaltered (I.: SFig. 
2D). The NICD downregulation was confirmed by immunohistochemistry staining, 
which showed less NICD throughout the whole colonic crypt in K8-/- colon compared 
to K8+/+ and K8+/- (I.: Fig. 3D). The decreased mRNA levels of Hey1 and Hey2 were also 
seen in K8-/- colon epithelium, which confirms lower Notch activity also in vivo (I.: Fig. 
3E). 
Since Notch1 target genes can be directly activated by colonic bacteria (Becker et 
al., 2013), we wanted to evaluate whether microbiota and inflammation affect the 
observed Notch phenotype in the K8-/- colon. After broad-spectrum antibiotic 
treatment for 8 weeks, a substantial decrease in FLN in the K8-/- colon was still 
observed (I.: SFig. 2E). This observation suggests that the Notch phenotype in the 
K8-/- colon is caused rather due to K8 loss than bacteria-induced inflammation. 
However, the evaluation of NICD as well as Hey1 and 2 levels are needed to further 
confirm this result. 
Active Notch signaling is known to induce enterocyte differentiation and inhibit goblet 
cell and EEC differentiation (Sancho et al., 2015). To test whether decrease in Notch 
activity has a further impact on cell differentiation in the K8-/- colon, the pattern and 
composition of enteroendocrine cells (EEC), enterocytes and goblet cells was evaluated 
in the colonic epithelium. The following markers have been used: villin for enterocytes 
(Robine et al., 1997), mucus/mucins for goblet cells (Garg et al., 2007) and synaptophysin 
for EEC (Thanasupawat et al., 2013). 
Villin protein levels were significantly decreased in K8-/- colon epithelium suggesting 
a reduced number of enterocytes (I.: Fig. 4A-B). This result was further confirmed by 
decreased mRNA levels of carbonic anhydrase 2 (CA2) in K8-/- colon, which is produced 
by enterocytes (I.: Fig. 4C). 
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Next, the amount of goblet cells was analyzed by Periodic acid-Schiff (PAS) staining, 
specific for goblet cells. Quantification of mucus positive cells revealed more goblet cells 
in the K8-/- colon in both proximal (PC) and distal (DC) parts compared to K8+/-. The 
amount of goblet cells in K8+/- colon was also increased in the distal part compared to 
K8+/+ (I.: Fig 4D, SFig. S3). However, the RT-PCR analysis of mucus components showed 
a significant increase in Mucin1 and Mucin2 (Kim and Ho, 2010) in K8-/- colon compared 
to K8+/+ (I.: Fig. 4E).
The immunoblotting against synaptophysin was done to analyze the amount of 
EEC cells. Synaptophysin levels in total colon lysate were significantly higher in the 
K8-/- compared to K8+/+ (I.: Fig. 4F-G). To confirm this result and visualize the 
position of EEC in the colon crypts, the immunofluorescent staining was performed. 
The synaptophysin was mostly stained in the crypt bottom in K8+/- and K8-/- colons. 
Interestingly, an increased number of EEC cells was observed in the K8-/- crypt 
bottom (I.: Fig. 4H b) compared to K8+/+ (I.: Fig. 4H a). Together, the data showed a 
decreased number of enterocytes and an increased number of goblet cells and EEC 
in K8-/- colon. 
The next aim was to characterize and compare the amount and localization of TA cells 
which differentiate into absorptive enterocytes and secretory cells in the colon, (Schepers 
and Clevers, 2012). Phosphohistone H3 (PHH3) was used as a marker of TA cells. 
Western blot analysis showed higher levels of PHH3 in the K8-/- and K8+/- epithelium 
compared to K8+/+ (I.: Fig. 5A-B), which was confirmed by the immunofluorescent 
staining (I.: Fig. 5C). Moreover, the 5-bromo-2’-deoxyuridine (BrdU) labeling, 4 h 
after injection, also showed an increase in the number of proliferative cells and wider 
proliferative zone in K8-/- colon crypts compared to K8+/+ (I.: SFig. 4 a-c). Interestingly, 
72 h after injection, only the K8+/+ cells clearly migrated to the top of the crypts compared 
to K8-/- and K8+/- crypts (I.: SFig. 4 d-f). Supportive for the impaired cell migration in 
K8-/- was a 60% decrease in the mRNA levels of its cell position regulator Ephrin type-B 
receptor 2 (EphB2) compared to K8+/+. The EphB2 levels were not significantly reduced 
in the K8+/- colon (I.: Fig. 5D). 
Taken together, the analysis of colonic cell types in K8-/- mice shows a shift towards the 
secretory cell differentiation in the absence of K8 (I.: Fig. 6, STable 1). This observation 
supports the decreased Notch1 activity in the K8-/- colon. The study also indicates that 
keratin dose-dependent hyperproliferation (Asghar et al., 2015) is due to an increased 
number of TA cells and their widened proliferative zone results in longer crypts in 
the K8-/- colon (Toivola et al., 2004; Habtezion et al., 2011). The data presented here 
are supported by other studies involving Notch and IFs, e.g. Notch1 regulated nestin 
expression (Shih and Holland, 2006) or reduced Notch1 signaling in GFAP-/-vim-/- 
astrocytes (Wilhelmsson et al., 2012). On the other hand, K14 downregulation in 
skin has been reported to lead to Notch1 increase (Alam et al., 2011b), while Notch 
downregulation in skin cancer decreased K13 and K15, but increased K17 levels 
(Sakamoto et al., 2012). 
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2. K8-deletion induced colitis is a risk factor for CRC development 
(Study II.)
Mutations in mainly K8 are reported in IBD patients (Buning et al., 2004; Owens et al., 
2004; Tao et al., 2007; Zupancic et al., 2014; Corfe et al., 2015a) and K8 deletion in mice 
leads to chronic colitis resembling human IBD. Since IBD is a well-known factor for 
developing CRC (Beaugerie and Itzkowitz, 2015), the aim was to investigate whether the 
K8-/- colon is prone to develop cancer. Moreover, epithelial cells hyperproliferate in the 
K8-/- colon (Toivola et al., 2004), which also might contribute to the CRC development.
2.1. Increased susceptibility of K8-/- colon to induced tumorigenesis 
indicates keratin involvement in colonic homeostasis
The examination of colons from both young and aging of K8-/- mice clearly revealed 
that they do not develop CRC spontaneously. Methylene blue staining of 9- month-old 
K8-/-, K8+/+ and K8+/- colons did not show any difference in the number of ACF, potential 
precursors of CRC (II.: SFig. 1A). Next, the susceptibility of K8-/- mice to develop 
cancer using two well-studied CRC models: AOM and ApcMin/+ was tested. The study 
with a single low dose (1 x 10 mg/kg) AOM treatment showed a significantly higher 
number of ACF in K8-/- colon compared to K8+/+ colon (II.: SFig. 1A). Multiple-dose 
AOM treatment (4 x 5mg/kg) led to tumor development mainly in the K8-/- colon, 
which displayed on average 6 tumors per mouse. K8+/+ and K8+/- colons developed one 
or no tumors, respectively upon the same treatment (II.: Fig. 1A-B). The K8-/- tumors 
were classified as tubular adenomas of high grade dysplasia compared to low grade 
dysplasia in K8+/+ tumors (II.: Fig. 1C). Moreover, the K8-/- tumors were nearly on 
average larger than K8+/+ tumors (3.2 ± 0.7 mm2 in K8-/- versus 1.6 ± 1.2 mm2 in K8+/+; 
p = 0.07). To determine whether colitis-induced tumorigenesis was affected by keratin-
levels, the AOM-DSS was administered to K8+/+ and K8+/- mice. The examination of the 
colons showed a 2-fold increase in the number of polyps in the K8+/- mice compared to 
K8+/+ (18 ± 12 polyps in K8+/- mice versus 9 ± 9 in K8+/+ mice), but this result did not reach 
statistical significance (p = 0.17), (II: SFig. 1B). 
Next, the susceptibility of K8-/- colon to develop CRC in the ApcMin/+ model was tested. K8-/- 
mice on FVB/N background were crossed with ApcMin/+ mice also on FVB/N background 
due to the K8-/- embryo lethality in the C57BL/6J strain (Baribault et al., 1993). Although, 
ApcMin/+ mice on C57BL/6J background develop numerous tumors in the small intestine 
(Moser et al., 1990), the tumorigenesis in the FVB/N strain is insignificant in either small 
or large intestine (Svendsen et al., 2011). The crosses of 4-6 month old K8-/-ApcMin/+ mice 
developed 11 ± 1.6 tumors, which were exclusively located in the distal colon and were 
classified as well differentiated intramucosal adenocarcinomas. No tumors were present 
in the intestinal tract of K8+/+ApcMin/+ or K8+/-ApcMin/+ mice (II.: Fig. 2A-C). However, 
treating these control mice with DSS for one week and no further treatment for 4 weeks 
resulted in colon tumor development, which was comparable between the genotypes (II.: 
SFig. 1C). 
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Keratins are known as biomarkers in tumor diagnostics. K7 expression is often 
decreased, while K20 is increased in colorectal adenocarcinomas. Moreover, 
decreased levels of K8 and K20 are observed in the tumors of epithelial-to-
mesenchymal transition, which is associated with higher metastatic potential and 
decreased survival in patients (Karantza, 2011). Aside from these, the role of keratins 
in the colon tumorigenesis remains ambiguous. Our results reveal that K8 deletion 
alone does not lead to spontaneous CRC development even at the old age of mice. 
Nevertheless, the results show a much higher susceptibility of the K8-/- colon to develop 
CRC in two models: AOM and ApcMin/+ models, which indicates the role of keratins 
in colon homeostasis. Since, K8-/- mouse colon displays both hyperproliferation and 
inflammation, we investigated which of these two processes is a triggering point for 
tumorigenesis. The experiments with AOM-DSS and DSS alone on K8+/+, K8-/- and 
K8+/+ApcMin/+, K8-/-ApcMin/+, clearly indicated that inflammatory environment, not 
hyperproliferation alone, is needed for the tumor development in the K8-/- colon. 
This is consistent with the fact that inflammation is one of the hallmarks of cancer 
(Hanahan and Weinberg, 2011). Furthermore, certain studies acknowledge keratins 
as the regulators of skin immunity (Roth et al., 2012), and the K8+/- mice display a 
slightly higher susceptibility to experimentally-induced colitis (Asghar et al., 2015). 
Also a recent proteomic study reported decreased K8, K18 and K19 levels in some IBD 
patients with a potential correlation to the development of CRC (Corfe et al., 2015), 
which supports the K8-/- colon phenotype. However, it remains to be determined 
whether humans or mouse models with disease-predisposing keratin mutations are 
more susceptible to CRC.
2.2. IL-22 pathway is involved in the K8-/- colon tumorigenesis
IL-22 is involved in tissue repair, inflammation and inflammation-induced 
carcinogenesis in many organs including colon. IL-22 levels are often elevated in 
IBD patients (Schmechel et al., 2008; Sonnenberg et al., 2011). Since the K8-/- colon 
hyperproliferates and develops colitis and is susceptible to CRC, we examined the 
levels of IL-22. RT-PCR results showed an over 6-fold increase in the IL-22 mRNA 
level of the K8-/- colon compared to K8+/+ and K8+/- colons (II.: Fig. 3A). IL-22 activity 
is negatively regulated by IL-22BP; thus its mRNA levels were also analyzed. The 
IL-22BP mRNA levels were increased 2-fold compared to K8+/+ (II.: Fig. 3B). On the 
contrary, western blot analysis revealed nearly a total loss of IL-22BP protein basally 
in both the total colon lysates and epithelium enriched fractions of K8-/- colons as 
well as in the tumor tissue of K8-/-ApcMin/+ colons. Interestingly, IL-22BP levels were 
intermediate in K8+/- and K8+/-ApcMin/+ colon (II.: Fig. 3C-E). The protein levels of 
IL-22RA1, an epithelial receptor of IL-22, were variable and relatively unchanged in 
K8-/- colon epithelium compared to K8+/+ and K8+/- (Fig. 14A). The activated state of 
IL-22 was confirmed by the elevated levels of its downstream effector - phosphorylated 
STAT3 (P-STAT3) in both K8-/- colon epithelium and K8-/-ApcMin/+ tumor tissue 
(II.: Fig. 3D-E). Furthermore, the RT-PCR analysis showed increased mRNA levels 
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of STAT3 target genes RegIIIγ and S100A11 (7.5-fold and 2-fold, respectively) in 
the K8-/- colon compared to K8+/+ (II.: SFig. 2). It has earlier been shown that active 
IL-22 and STAT3 signaling can indicate tissue damage and therefore activated defense 
mechanisms; thus, the colonic barrier capacity was analyzed. Oral administration of 
fluorescent dextran (FD4) detected a break of the intestinal barrier in K8-/- mice 
compared to K8+/+ and K8+/- (II.: Fig. 4E). However, these results are somewhat 
contradictory to previous K8-/- colon permeability studies (Toivola et al., 2004); thus 
further work is needed to clarify the colonic barrier of K8-/- colon. In addition, the 
upstream of IL-22BP signaling was investigated which, according to the current 
literature, is barely known. Since one of the studies suggests IL-18 as an inhibitor of 
IL-22BP expression, IL-18 levels were examined by western blot. The IL-18 protein 
levels were elevated up to 20-fold in the colonic epithelium of K8-/- compared to K8+/+ 
and K8+/- (II.: Fig. 4C). Similar to IL-22BP, the levels of IL-18 were intermediate in 
K8+/- colon epithelium compared to other genotypes (5.7-fold increase compared to 
K8+/+, p = 0.05 in Student’s t-test), (II.: Fig. 4C). 
Our results showed dramatically increased levels of IL-22 in the K8-/- mouse colon. 
Interestingly, no difference in the levels of colonic IL-22 was detected between K8+/+ 
and K8+/- mice, which likely explains why no tumors are developed in these animals. 
The IL-22 activity is neutralized by IL-22BP, a receptor known to be downregulated 
during tissue damage (Kotenko et al., 2001; Huber et al., 2012). IL-22BP-/- mice, apart 
from prolonged IL-22 signaling and epithelial tissue repair, develop an increased 
number of colonic tumors in AOM/DSS and ApcMin/+ models (Huber at al., 2012). 
Our data indicated a dramatically decreased or a total lack of IL-22BP protein in the 
K8-/- colon, both basally and in the tumor tissue of K8-/-ApcMin/+ mice (II.: Fig. 3C-E). 
Recently, two mouse models: STING (stimulator of interferon signaling)-knock-out 
mice and Rag-APC natural killer cell depleted mice have been reported to express 
decreased IL-22BP levels during induced tumorigenesis (Janakiram et al., 2014; Ahn et 
al., 2015). To our knowledge, K8-/- is the only mouse model so far, which presents such 
a strong downregulation/lack of IL-22BP protein under basal conditions. Supportive 
to the regulatory role of keratins in IL-22BP expression are the intermediate levels 
of IL-22BP between K8+/+ and K8+/- colon, which has 50% less keratin filaments. IL-
22BP regulation likely occurs on a posttranslational level, since IL-22BP mRNA levels 
were not decreased in the K8-/- colon. Moreover, the treatment with broad-spectrum 
antibiotics, which alleviates colitis in K8-/- mice, has not influenced the levels of 
expressed IL-22BP (Fig. 14B) indicating likely no involvement of bacteria in the 
observed phenotype. 
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Figure 14. Colonic IL-22RA1 protein levels are variable in K8-/- mouse and colonic IL-22BP 
levels do not increase upon antibiotic treatment. A. The IL-22RA1 western blot analysis of colon 
epithelial samples from baseline K8+/+, K8-/- and K8+/- mice, display variable protein levels in all 
genotypes. Equal amounts of proteins were loaded after normalization by protein assay, as shown 
by Hsc70 loading control. B.-C. The colonic microflora of K8+/+, K8-/- and K8+/- mice was depleted 
by broad-spectrum antibiotics vancomycin and imipenem (+Abx) and IL-22BP, K8 and Hsc70 
levels were analyzed. Antibiotics were administered in drinking water at 68 mg/kg body weight per 
day for 8 weeks starting at 18-19 days postnatally. Control mice received normal drinking water 
(-Abx). Equal amounts of proteins were loaded after normalization by protein assay, as shown by 
the Hsc70 loading control. 
Active IL-22/IL-22BP signaling is known to be required in tissue repair in the colon via 
the JAK/STAT pathway (Huber et al., 2012). The studies with FD4 revealed a disruption 
in the K8-/- colon tissue integrity, further confirmed by elevated mRNA levels of S100A11 
and RegIIIγ antimicrobial products. Also increased basal levels of P-STAT3 were 
observed in K8-/- colon epithelium compared to K8+/+ and K8-/- epithelium (II.: Fig. 3D). 
There was no difference in P-STAT3 levels of the total colon lysates (II.: Fig. 3C), which 
is likely due to the P-STAT3 signal coming from immune cells in the lamina propria. 
Even higher levels of P-STAT3 were observed in colonic tumors of K8-/-ApcMin/+ mice 
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(II.: Fig. 3E), which is consistent with an oncogenic role of P-STAT3 (Levy and Inghirami, 
2006). Recently, it has been shown that IL-22 is able to upregulate K17 in keratinocytes 
via STAT3 and Erk1/2 pathway, which could suggest a compensatory role of IL-22 
in the lack of K8 in the colon. Our studies also focused on the role of IL-18, as it was 
proposed to negatively regulate the levels of IL-22BP. As detected by Western blotting, 
IL-18 expression in the K8-/- colon epithelium was highly upregulated, which provides 
support for IL-22BP regulation. Similarly, to IL-22BP, IL-18 expression was intermediate 
between K8+/+ and K8+/- colon epithelium, which demonstrates keratin involvement in 
the upstream processes from IL-18.
2.3. K8 binds the inflammasome - a potentially new cytoskeletal 
contributor to the IL-22 pathway
IL-18 is processed into mature form by an active NLRP3 inflammasome from which 
caspase-1 is released (Huber et al., 2012). In agreement with the IL-18 results, we 
observed elevated levels of active caspase-1 exclusively in K8-/- and K8-/-ApcMin/+ colons 
(II.: Fig. 4A-C). To address the involvement of keratins in the IL-22 pathway, K8/K18 
were immunoprecipitated from the colonic epithelium of K8+/+ mice. Pro-caspase-1, 
a  component of inflammasome co-immunoprecipitated with K8/K18 from both 
proximal and distal colon (II: Figure 4D), which indicates a potential interaction between 
these proteins. In summary, the results show the binding of intestinal keratins to the 
inflammasome and in the lack of K8 increased inflammasome activity. Supportive to 
these data is the keratin 1 knock-out (Krt1-/-) mouse model, in which inflammasome-
dependent IL-18 upregulation together with increased production of antimicrobial 
ligands S100A8 and S100A9 are observed in keratinocytes with an inflammatory 
skin disease phenotype (Roth et al., 2012). Inflammasomes, similar to keratins, act 
as cytoplasmic sensors of cellular stress upon which they are activated (Schroder and 
Tschopp, 2010; Toivola et al., 2010). Common stress stimuli might shed more light on 
the keratin-inflammasome interactions. Interestingly, inflammasomes are also activated 
by toll-like receptors (TLR) (Fernandes-Alnemri et al., 2013) and TLR9 is upregulated 
in the K8-/- colon (Habtezion et al., 2011). Microarray data from experimental colitis of 
C57BL/6 mice identified keratins as major genes upregulated during the recovery phase 
(Breynaert et al., 2013), which confirms the stress-protective role of keratins essential 
for healing and repair of the colon. Recently, a mesenchymal IF, vimentin, was shown 
to bind to NLRP3 inflammasome and lead to its activation (dos Santos et al., 2015). 
In contrast to K8-/- mice, vimentin knock-out mice in that study were protected from 
lung inflammation and injury, which was associated with an active inflammasome. This 
discrepancy could be due to the different inflammasome localization- mesenchymal vs. 
epithelial and more tissue specific studies are needed to resolve this issue. Taken together, 
our data nominate keratins as novel ligands that bind inflammasome and elicit intestinal 
epithelial cell inflammasome activation and, that thus, can regulate the IL-22 pathway. 
Essential for further studies, is to analyze which inflammasome type is central in this 
process.
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3. K8 influences colon energy metabolism (Study III.)
The main source of colonocyte energy is SCFA produced by bacterial fermentation of 
starch and carbohydrates. SCFAs are mainly transported to the colon epithelial cells via 
the monocarboxylate transporters, like MCT1. Butyrate, the major SCFA produced in the 
colon, regulates the levels of mitochondrial HMGCS2, which is a rate limiting enzyme of 
ketogenesis. Intriguingly, HMGCS2 turned out to be the major downregulated protein in 
K8-/- colonocytes. Thus the aim was to determine whether and how keratins are involved 
in the regulation of colon energy metabolism.
3.1. HMGCS2 downregulation is K8-/- colon specific and leads to blunted 
ketogenesis
2D DIGE and mass spectrometry were performed to identify differentially regulated 
proteins in K8+/+ and K8-/- colonocytes (III.: Fig.1A-B). Apart from the expected 
downregulation of K8 and K19, a group of mitochondrial, cytoplasmic and endoplasmic 
reticulum proteins was found most differentially expressed in K8-/- colonocytes (III: STable 
1). Among these proteins was HMGCS2, a mitochondrial enzyme of ketogenesis, which 
displayed a 4-fold decrease in K8-/- colonocytes (III.: Fig. 1A-B, spots 1032, 1033, 1035 
and 1044) compared with K8+/+. This finding was subsequently confirmed by HMGCS2 
immunoblotting of K8+/+ and K8-/- colon crypts (III.: Fig. 1C). A slight downregulation 
of HMGCS2 was also observed in vitro in Caco-2 and HT-29 human colorectal cancer 
cells, when K8 levels were decreased by siRNA silencing (III.: SFigure 1). To examine if 
K8-/- loss also affected HMGCS2 enzyme activity, the evaluation of both HMGCS2 activity 
and quantity was performed on the same set of mitochondria isolated from colonic 
epithelium. The results clearly showed a parallel downregulation of HMGCS2 protein 
quantity and enzyme activity in K8-/- colonic epithelium compared to K8+/+ (III.: Fig. 
1D-E). As revealed by HMGCS2 activity/quantity ratio, the decrease in enzyme quantity 
correlated with the decrease in enzyme activity in K8-/- colon (III.: Fig. 1F). 
Next, we investigated whether HMGCS2 downregulation appears exclusively in the colon 
or also in other organs. The protein lysates from proximal and distal colon, small intestine 
and liver were analyzed by immunoblotting and the results showed that HMGCS2 
downregulation occurs only in the colon (III.: Fig. 2A and C, SFig. 3). The blot also 
indicated higher levels of HMGCS2 expression in the proximal than in the distal colon, 
which is likely due to a higher number of SCFA-producing bacteria in the mouse proximal 
colon than in the distal colon (Hamer et al., 2008). The HMGCS2 downregulation in 
K8-/- colonocytes was also detected by the immunostaining and the remaining HMGCS2 
was localized in the apical part of the K8-/- cells (III.: Fig. 2B). As previously reported, 
HMGCS2 is not expressed in the small intestine, but highly expressed in the liver, which 
was confirmed by our results. Interestingly, there were no major differences in HMGCS2 
expression observed between K8+/+ and K8-/- livers (III.: Fig. 2C and SFig. 3). In addition 
to these results, the levels of the HMGCS2 transcription factor – PPARα were also found 
downregulated in K8-/- colon (III.: Fig. 2A). Since K8-/- mice spontaneously develop 
56 Results and Discussion 
colitis, it is possible that the inflammation leads to the downregulation of the HMGCS2 
levels. However, the treatment of BALB/c mice with the colitis inducing reagent, DSS, 
resulted in unchanged or increased levels of HMGCS2 (III.: Fig. 2D). 
Further, the response of K8-/- colonocytes to ketogenic conditions was analyzed. The mice 
were starved for 12 and 24 hours or fed with a ketogenic diet for 3 or 14 days, after 
which HMGCS2, blood glucose, and blood β-hydroxybutyrate levels were determined. 
Starvation for both 12 and 24 h induced ketogenic conditions, since blood glucose levels 
decreased and blood β-hydroxybutyrate levels increased at the same time (III.: Fig. 3A-
B). Ketogenic diet did not influence glucose levels, but β-hydroxybutyrate levels were 
significantly upregulated after 14 days in both K8+/+ and K8-/- mice, which indicates 
induced ketogenic conditions (III.: Fig. 3C-D). Moreover, serum parameters including 
cholesterol, bicarbonate and triglycerides were assayed and no major differences between 
the genotypes and control versus ketogenic group were detected besides decreased 
cholesterol levels in K8-/- mice upon 7 days of ketogenic diet (III.: Fig. 3E). At the same 
time, the food ingestion and mouse weight were monitored and no differences were 
observed (III.: SFig. 4). These data provide further evidence for unaffected ketogenesis in 
K8-/- liver and show a suitability of these ketogenic conditions to study colon ketogenesis. 
The colonic HMGCS2 levels were upregulated in K8+/+ mice upon starvation and 
ketogenic diet for 3 days, in contrast to K8-/- mice, whose colonic HMGGCS2 levels were 
not significantly increased upon ketogenic conditions (III.: Fig. 4A-F). A similar trend 
of HMGCS2 mRNA increase was observed in K8+/+ under ketogenic conditions, while in 
K8-/-, the HMGCS2 mRNA remained almost unchanged (III.: Fig. 4G). The expression 
of PPARα followed HMGCS2 expression pattern and displayed a slight upregulation in 
K8+/+ and a slight downregulation in K8-/- colon under ketogenic conditions (III.: Fig. 4A, 
C, E). These results clearly indicate a blunted ketogenesis in K8-null colonocytes.
Altogether, the proteomic studies revealed HMGCS2 as a major downregulated protein 
in the K8-/- colonocytes. This observation was colon specific and no major HMGCS2 
downregulation was detected in the liver of K8-null mice, although liver is the main 
ketogenic organ where keratins are highly expressed and have cytoprotective roles 
(Hegardt, 1999; Ku et al., 2007). Interestingly, HMGCS2 downregulation in the mouse liver 
has recently been reported to contribute to the inflammatory liver disease, steatohepatitis 
(Cotter et al., 2014). On the other hand, it is very probable that microbiota contribute to 
colonic HMGCS2 downregulation. Supportive for this hypothesis is the regulatory role 
of bacterially produced SCFA on HMGCS2 expression (Cherbuy et al., 2004) and the 
presence of fewer luminal bacteria in the K8-/- colon (Habtezion et al., 2011). Another 
factor modulating HMGCS2, which should be taken into consideration, is the colitis 
developed by K8-/- mice. Our results with DSS-induced colitis in BALB/c mice showed 
no effect or an increase in HMGCS2 expression, which is in line with a previous study 
(Naito et al., 2010) and suggests that HMGCS2 downregulation is specifically caused 
by the lack of K8 but not inflammation per se. In addition, the results clearly showed 
that K8-/- colon was not able to increase HMGCS2 levels under the ketogenic conditions 
compared to K8+/+. 
 Results and Discussion 57
3.2. Colon mitochondria and energy intermediates are largely unaffected 
after K8 inactivation
Since ketogenesis occurs in the mitochondria and is linked to other metabolic pathways, 
we investigated their potential impact on HMGCS2 downregulation in the K8-/- colon. 
Electron microscopy showed that there was no difference between the size of K8-/- and 
K8+/+ colonic mitochondria, although fewer cristae per mitochondria were present in 
the K8-/- (III: SFig. 5B-C). On the contrary, hepatic mitochondria of K8-/- are smaller 
than K8+/+ (Tao et al., 2009). Moreover, the mitochondrial function of K8-/- and K8+/+ 
colons was comparable, since no changes in the protein levels of mitochondrial markers, 
prohibitin and cytochrome c, were detected (III.: SFig. 2B). 
Next, we analyzed a group of protein involved in the colon energy metabolism, under 
both basal and ketogenic conditions. Acetyl-CoA carboxylase (ACC) converts acetyl-
CoA into malonyl-CoA during fatty acid biosynthesis and inhibits β-oxidation. 
Ketogenic conditions stimulate the β-oxidation of fatty acids into acetyl-CoA to 
maintain the substrate for ketone bodies production, while ACC activity is low 
(Lopaschuk et al., 2010). The colonic levels of ACC were unaltered in both K8+/+ and 
K8-/- basally, while a 3-day ketogenic diet induced a significant 2.5-fold decrease in ACC 
expression in the K8+/+ colon and nonsignificant 1.4-fold decrease in the K8-/- colon (III.: 
SFig. 6 A-C). This observation supports that the ketogenic pathway is blunted in the 
K8-/- colonocytes. However, nonsignificant changes in the expression of ACC inhibitors: 
adenosine monophosphate-activated protein kinase α and β1 (AMPKα and AMPKβ1) 
either in K8+/+ or K8-/- colons were detected under either basal or ketogenic conditions. 
The inactive phosphorylated forms of AMPKs; P-AMPKα and P-AMPKβ1, were also 
unaltered. Interestingly, the expression levels of glucose transporter 4 (GLUT4) and 
cytochrome c oxidase (COX IV) were slightly decreased in the K8-/- colon regardless of 
the conditions, whereas the same analysis on the colon epithelial scrapings did not show 
any differences (not shown). The ratios of ADP/ATP and NAD/NADH produced in the 
K8+/+ and K8-/- colons were also comparable (not shown).
In summary, the data from K8-/- colon show blunted ketogenesis. Although fewer cristae 
are present in K8-/- colonic mitochondria, they do not affect the overall size of the 
organelles. Interestingly, the decreased number of cristae has previously been linked to the 
downregulation of prohibitin and subsequent impairment in proliferation and resistance 
to apoptosis (Merkwirth et al., 2008), the two latter once of which are the characteristics 
of K8-/- colon. On the other hand, comparable levels of prohibitin in the mitochondria 
between the K8+/+ and K8-/- colon (III.: SFig. 2) exclude its direct involvement in the 
K8-/- phenotype. In addition to this, protein levels of ACC in the K8-/- colon do not decrease 
upon ketogenic conditions, which suggests diminished β-oxidation. As mentioned 
previously, β-oxidation provides mitochondria with acetyl-CoA, which is a building 
block for ketone body production; thus, its inhibition during ketogenic conditions can 
contribute to the blunted ketogenesis of K8-/- colon. Previous studies showed that K8/K18 
can inhibit the activity of hepatic carnitine palmitoyltransferase I (CPTI), the rate limiting 
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enzyme of β-oxidation (Velasco et al., 1998). Moreover, impaired expression of proteins 
involved in ketogenesis and β-oxidation have been reported in the cardiac muscles of 
desmin knock-out mice (Fountoulakis et al., 2005). Nevertheless, further studies are 
needed to determine whether and how colonic keratins regulate the β-oxidation pathway. 
3.3. K8-/- colon has increased levels of luminal SCFAs but decreased levels of 
their transporter MCT1
The lack of butyrate-producing bacteria leads to reduced metabolism in germ-free mice 
(Donohoe et al., 2011). It is also known that the colonic SCFA concentration regulates the 
expression of HMGCS2 (Cherbuy et al., 2004). Since HMGCS2 levels are only altered in 
the K8-/- colon, which is populated by fewer microorganisms than K8+/+ colon (Habtezion 
et al., 2011), the SCFA levels and transport into colonic cells were examined. The main 
SCFA transporter, MCT1 was downregulated in the K8-/- total colon lysates as well as 
in its epithelial fractions (isolated from both starved and unstarved mice) compared 
to K8+/+ (III.: Fig. 5A-C). This observation was confirmed in vitro in the K8-silenced 
HT-29 and Caco-2 cell lines (III.: SFig. 1). The MCT1 immunostaining of K8-siRNA 
silenced Caco-2 cells and K8-null colon did not show any changes in protein localization, 
which was plasma membrane specific in the cells and mainly laterally distributed within 
the epithelium of K8-/- colon (III.: SFig. 7). As the increase in butyrate concentration 
upregulates MCT1 levels, the ratio of butyrate-producing bacteria to total Eubacteria in 
K8+/+ and K8-/- stool was also analyzed. No differences between the number of Clostridial 
clusters XIVa and IV in K8+/+ and K8-/- colons were detected (III.: Fig. 6A). However, 
the SCFA analysis revealed increased butyrate and isobutyrate levels in the K8-/- stool 
compared to K8+/+ (III.: Fig. 6B). 
Taken together, the data show that K8 absence is accompanied with MCT1 downregulation 
and butyrate increase in the colonic lumen. Similar observations of K8 downregulation 
and butyrate increase were made before in human colorectal cancer tumors (Khan et al., 
2011). Interestingly, increased levels of butyrate do not result from the changes in the 
ratios of butyrate-producing bacteria to the K8-/- microbiome. Simultaneous increase in 
the concentration of luminal butyrate points towards its impaired transport through the 
K8-/- epithelium. This hypothesis is supported by low levels of the butyrate transporter 
MCT1 detected in K8-/- colonic epithelium. Since there is less butyrate transported, 
which is a substrate for ketogenesis, the HMGCS2 expression levels remain low. Keratins 
could be involved in the SCFA transport by targeting MCT1 to the cell membrane. 
Previously, mislocalization of the ion transporter AE1/2 and ENACγ has been reported 
in the K8-/- colon (Toivola et al., 2004). Moreover, lack of epithelial keratins was linked to 
the mislocalization of GLUT transporters in embryo (Vijayaraj et al., 2009) and pancreas 
(Alam et al., 2013). However, apart from downregulated levels of MCT1, we did not note 
any mistargeting of MCT1 in either the K8-/- colon or K8-siRNA silenced Caco-2 cells 
(III. SFig. 7). This would suggest the involvement of keratin in the stability of MCT1. 
The analysis of MCT1 levels in K8 silenced Caco-2 cells with overexpression of MCT1 
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(Fig. 15) further confirms a direct relationship between MCT1 and K8. In summary, the 
observed disruption of SCFA-MCT1-HMGCS2 axis in K8-/- colonocytes indicates the 
regulatory role of keratins in colon energy metabolism.
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Figure 15. MCT1 levels are dependent on K8 expression. A. K8 silenced cells transfected with 
MCT1 show a significant inability to overexpress MCT1. Equal amounts of proteins were loaded 
after normalization by protein assay, as shown by β-tubulin loading control B. K8 and MCT1-
GFP levels were quantified with ImageJ and normalized to β-tubulin (B., average ± SD, *p < 0.05, 
**p < 0.01).
4. Future prospects in the colon keratin field
The first major evidence for involvement of keratin in colon diseases was described in 
1994 upon the generation of the K8-/- mouse, which spontaneously developed an early 
chronic colitis (Baribault et al., 1994). Since then, studies have indicated keratin mutations 
in IBD patients (Owens et al., 2004; Tao et al., 2007; Corfe et al., 2015). Although certain 
studies reported disturbed filament assembly and compromised intestinal barrier 
(Zupancic et al., 2014), still not much is known about the molecular consequences of 
keratin mutations in the colon. A strong contribution to the field would bring the screen 
for most commonly occurring keratin mutations in a big cohort of IBD patients as well as 
generation of mouse models carrying the most prominent human mutations.
The functions of keratin IFs are regulated by various PTMs (Snider and Omary, 2014), 
which have not been fully validated for either healthy or diseased colonic mucosa. Also, 
the keratin binding drugs have not been discovered yet and their presence would certainly 
facilitate studies regarding the role of keratins in the colon.
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Keratins have been commonly used as diagnostic tools in cancer (Karantza, 2011) and 
their significance as prognostic markers is rising. Decreased expression levels of K8 and 
K20 have been observed in EMT and are linked to more aggressive phenotypes of CRC 
tumors (Knosel et al., 2006). Also detection of caspase-cleaved K18 fragments in the 
sera of CRC patients with a tumor resection has been linked with disease recurrence 
(Ausch et al., 2009). Interestingly, recent studies have found a population of K19 positive 
intestinal stem cells, which are radioresistant and give rise to the CRC (Asfaha et al., 
2015). However, how exactly keratins contribute to the development of CRC still remains 
an open question. 
The novel genome editing tool CRISPR/Cas9 could be successfully used in modifying 
keratin expression in at least cancer colon cell lines. This would enable further analysis of 
cancer cell properties, like cell ability to metastasize depending on the keratin expression 
pattern. Promising is also an organoid biobank of colorectal cancer patients (van de 
Wetering et al., 2015), which might be screened from the keratin point of view. Essential 
in future studies is also the use of novel bioimaging techniques including stimulated 
emission depletion microscopy (STED) and fluorescence resonance energy transfer 
(FRET). The proximity ligation assay (PLA) and optogenetics also compromise potent 
tools in analyzing keratin dynamics and finding its novel binding partners (Zatloukal et 
al., 2014; Isogai et al., 2015).
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SUMMARY
The aim of this thesis was to study the role of keratin IFs in the colon. 
In this work, new aspects of keratin involvement in Notch signaling, inflammation-
induced colorectal cancer as well as energy metabolism were rised. The main findings of 
this study are summarized in Fig. 16 and are as follows:
1. By binding to Notch1 in vitro and in vivo, K8 enhances Notch1 signaling activity 
and target gene transcription. The loss of K8 in the colon leads to a dramatic 
decrease in Notch1, which alters epithelial cell differentiation. 
2. Deletion of K8 results in spontaneous colitis, which increases the susceptibility to 
develop colorectal tumors in two cancer models: AOM and ApcMin/+. K8-/-ApcMin/+ 
mice, thus, could be used as a model for colitis-induced colorectal cancer. The 
tumorigenesis is enhanced by an activated inflammasome, which keratins can 
bind to in vivo, and a constantly active IL-22 signaling pathway due to the lack of 
its negative regulator IL-22BP protein. 
3. The K8-/- epithelium displays reduced levels of the butyrate transporter, MCT1. 
This decreases the transport of SCFA through colonic epithelial membranes and 
leads to diminished HMGCS2 levels in colonocytes. Blunted ketogenesis in K8-/- 
colon may lead to alterations in energy metabolism.
The lack of K8
in colonic epithelium
Notch1
Hey1, Hey2
Shifted differentiation
towards goblet and 
enteroendocrine cells
caspase-1  
Active IL-22 pathway
Increased susceptibility 
to induced CRC
MCT1
Blunted ketogenesis 
HMGCS2
1. 2. 3.
Figure 16. The consequences of K8 absence to the colonic epithelium – the key findings of the 
thesis. Study 1. The lack of keratin 8 (K8) leads to a decrease in Notch1 and Hey1 and Hey2. The 
lower activity of Notch1 results in a shifted cell differentiation towards goblet and enteroendocrine 
cells. Study 2. The absence of K8 increases caspase-1 levels released from the inflammasome, 
which activates the IL-22 pathway. A constantly active IL-22 pathway contributes to increased 
susceptibility of K8-/- mice to induced colorectal cancer (CRC). Study 3. The levels of the SCFA 
transporter - MCT1 are decreased in the K8-/- colonic epithelium. Impaired SCFA transport 
decreases the levels of the ketogenic enzyme HMGCS2, which leads to blunted ketogenesis. 
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